[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 163
6. Jensen SA, Vilmar A, Sørensen JB: Adjuvant chemotherapy in elderly patients (>or=75 yr) completely resected for colon cancer stage III compared to younger patients: toxicity and prognosis. Med Oncol; 2006;23(4):521-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy in elderly patients (>or=75 yr) completely resected for colon cancer stage III compared to younger patients: toxicity and prognosis.
  • PURPOSE: To compare benefits and risks to adjuvant chemotherapy following complete resection of node-positive colon cancer stage III for patients aged >or=75 yr and younger.
  • CONCLUSIONS: Adjuvant 5-FU chemotherapy should be considered for elderly patients aged >or=75 yr in good performance at high risk of recurrence of colon carcinoma after resection.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colonic Neoplasms / drug therapy

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3992-8 [12351596.001]
  • [Cites] Ann Intern Med. 2002 Mar 5;136(5):349-57 [11874307.001]
  • [Cites] Cancer Control. 1995 Mar;2(2 Suppl 1):36-38 [10887408.001]
  • [Cites] Pharmacol Rev. 2004 Jun;56(2):163-84 [15169926.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):850-7 [11390534.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):899-906 [8143995.001]
  • [Cites] Lancet. 1999 Jan 30;353(9150):391-9 [9950460.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):1931-8 [11932894.001]
  • [Cites] Lancet. 2000 May 6;355(9215):1588-96 [10821362.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2412-8 [10561304.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]
  • [Cites] Ann Oncol. 2004 Apr;15(4):568-73 [15033660.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2896-903 [12885807.001]
  • [Cites] Am J Clin Oncol. 2003 Feb;26(1):103-6 [12576935.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] Ann Oncol. 2005 May;16(5):767-72 [15817594.001]
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2061-7 [10615079.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] Cancer J. 2001 May-Jun;7(3):213-8 [11419029.001]
  • [Cites] Lancet. 1995 Apr 15;345(8955):939-44 [7715291.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1447-56 [2778478.001]
  • [Cites] Am J Clin Oncol. 1982 Apr;5(2):227-36 [7091044.001]
  • [Cites] Ann Oncol. 2000 Aug;11(8):947-55 [11038030.001]
  • [Cites] J Clin Oncol. 1984 Jul;2(7):849-55 [6737023.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):295-300 [9440756.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3553-9 [10550154.001]
  • [Cites] Cancer. 1995 Feb 1;75(3):775-81 [7828127.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):918-26 [8756390.001]
  • [Cites] Lancet. 2000 May 20;355(9217):1745-50 [10832824.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • (PMID = 17303911.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Dahl O, Fluge Ø, Carlsen E, Wiig JN, Myrvold HE, Vonen B, Podhorny N, Bjerkeset O, Eide TJ, Halvorsen TB, Tveit KM, Norwegian Gastrointestinal Cancer Group: Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncol; 2009;48(3):368-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
  • BACKGROUND: The recommendation of adjuvant chemotherapy for colon cancer with lymph node metastases, based on two studies from USA, was reluctantly accepted by Norwegian medical doctors.
  • MATERIAL AND METHODS: Four hundred and twenty five patients with operable colon and rectum cancer, Stage II and III (Dukes' stage B and C), were from January 1993 to October 1996, included in a randomised multicentre trial in Norway.
  • There was no difference between the two groups when analysed for colon and rectum separately.
  • However, the subgroup of colon cancer with stage III exhibited a statistically significant difference both for DFS, 58% vs. 37% (p=0.012) and CSS, 65% vs. 47% (p=0.032) in favour of adjuvant chemotherapy.
  • CONCLUSIONS: Colon cancer patients with lymph node metastases benefit from adjuvant chemotherapy with 5-FU/Lev with acceptable toxicity.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Antirheumatic Agents / therapeutic use. Colonic Neoplasms / drug therapy. Fluorouracil / therapeutic use. Levamisole / therapeutic use. Rectal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19242829.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antirheumatic Agents; 2880D3468G / Levamisole; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Snaebjörnsson P, Jónasson L, Jónsson T, Möller PH, Theodórs A, Jónasson JG: [Colon cancer in Iceland 1955-2004. Study on epidemiology, histopathology and gender difference]. Laeknabladid; 2009 Jun;95(6):423-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colon cancer in Iceland 1955-2004. Study on epidemiology, histopathology and gender difference].
  • OBJECTIVE: Colon cancer is the third most common cancer in Iceland.
  • The aim of this study was to analyze the epidemiology and histopathology of colon cancer in Iceland, resection rate and the difference between men and women.
  • MATERIAL AND METHODS: Pathology and autopsy reports for all patients diagnosed with colon cancer between 1955 and 2004 where reviewed.
  • Most tumors were located in the sigmoid colon (35%).
  • Adenocarcinomas where 84% and mucinous adenocarcinoma 7%.
  • Altogether 7% of cases were TNM-stage I, 32% were stage II, 24% stage III, 21% in stage IV and stage was unknown in 16% of cases.
  • CONCLUSION: Incidence of colon cancer increased considerably, mainly for men.
  • Surgical rate and pathology of colon cancer is similar to that reported elsewhere except that there are somewhat fewer cases in TNM-stage I.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma, Mucinous / epidemiology. Colonic Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Laeknabladid. 2009 Jun;95(6):419 [19491405.001]
  • (PMID = 19491407.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


9. Silvéra L, Galula G, Tiret E, Louvet C, Leroux JL, Trutt B: Assessment of management practices for colonic cancer in the Paris metropolitan area in 2002. Gastroenterol Clin Biol; 2006 Jun-Jul;30(6-7):852-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the management of patients aged 18 years or older with colonic adenocarcinoma (including the rectosigmoid junction), compared with French guidelines (ANAES and SOR).
  • METHODS: This retrospective study carried out in 2003 by the Ile-de-France regional union of health insurance funds from hospital discharge and operative and pathology reports of patients exempted from copayment between April 2001 and March 2002.
  • 37.7% of stage II patients had chemotherapy while 10.8% of stage III and 9.8% of stage IV patients did not.
  • CONCLUSION: Implementation of guidelines for the management of colon cancer can be improved, notably regarding pathologic analysis and indications of chemotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Colonic Neoplasms / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Colon / pathology. Data Collection. Data Interpretation, Statistical. Female. Guideline Adherence. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary / therapy. Paris. Practice Guidelines as Topic. Retrospective Studies. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885869.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] France
  •  go-up   go-down


10. Colomer A, Erill N, Vidal A, Calvo M, Roman R, Verdú M, Cordon-Cardo C, Puig X: A novel logistic model based on clinicopathological features predicts microsatellite instability in colorectal carcinomas. Diagn Mol Pathol; 2005 Dec;14(4):213-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-frequency microsatellite instability has been reported to be associated with good prognosis in colorectal adenocarcinoma.
  • Clinicopathological features of a cohort of 204 patients with primary colon cancer were retrospectively reviewed following predetermined criteria.
  • Implementation of this tool to routine histopathological studies could improve the management of patients with colorectal cancer, especially those presenting with stage II and III of the disease.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16319691.001).
  • [ISSN] 1052-9551
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


11. Shaikh AJ, Raza S, Shaikh AA, Idress R, Kumar S, Rasheed YA, Lal A, Masood N: Demographics, pathologic patterns and long-term survival in operable colon cancers: local experience in Pakistan. Asian Pac J Cancer Prev; 2009 Jul-Sep;10(3):361-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Demographics, pathologic patterns and long-term survival in operable colon cancers: local experience in Pakistan.
  • BACKGROUND: Colon cancer is a common malignancy with its incidence reportedly rising in Asian countries, including Pakistan.
  • There are no comprehensive data available from Pakistan which focus on associations of various factors with long-term survival of colon cancer.
  • METHODOLOGY: In this retrospective study adult patients with colon cancer diagnosed through 2000-2003 were included.
  • Of the total, 49.5% of the patients had right sided (mortality rate 51.6%), 10.8% had transverse colon, (mortality rate 37.5%), 7.5% had descending colon (mortality rate 66.7%) and 32.2% had sigmoid colon (mortality rate 40.9%) cancers.
  • Stage I disease on diagnosis was found in 16%, stage II in 42.7 (mortality 40 %) and stage III in 41.3% (mortality 70 %).
  • Most patients had pure adenocarcinoma while a mucinous type differentiation was seen in 19.7%, 3% had signet ring morphology, 1.5% adeno-squamous carcinoma and similar number with neuroendocrine differentiation.
  • CONCLUSION: Colon cancer in Pakistan commonly presents at an advanced stage, there is a male preponderance, and relatively mean younger age at presentation for males is seen.
  • Advanced stage and lymph node involvement along with poorly differentiated pathology, signet ring or mucinous morphology, location in descending colon, positive surgical margins and removal of less than twelve lymph nodes are factors associated with poor long term survival.
  • There is a need to reinforce information about colon cancer and larger studies from the region are needed to confirm the factors analyzed here.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Neoplasm Recurrence, Local / mortality. Survivors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19640173.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


12. Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK, Park YS: Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol; 2010 Sep;66(4):659-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
  • PURPOSE: Colon cancer with DNA mismatch repair (MMR) defects reveals indistinguishable clinical and pathologic aspects, including better prognosis and reduced response to 5-fluorouracil (5-FU)-based chemotherapy.
  • This study investigated the clinical implication of MSI-H/MMR-D and p53 expression in R0-resected colon cancer patients who received adjuvant oxaliplatin/5-FU/leucovorin (FOLFOX) therapy.
  • EXPERIMENTAL DESIGN: We analyzed 135 patients, who had been treated by adjuvant chemotherapy containing 5-FU and oxaliplatin (FOLFOX) after curative resection (R0) for colon adenocarcinoma between May 2004 and November 2007.
  • RESULTS: There were 13 (9.6%) patients with stage II, 108 (80%) with stage III, and 14 (10.4%) with stage IV.
  • Fourteen patients with stage IV (10.3%) had metastases to liver only, all of whom underwent complete metastasectomy for liver metastases.
  • MMR status was not significantly associated with DFS (P = 0.56) or OS (P = 0.61) in patients with colon cancer (n = 135) receiving adjuvant FOLFOX.
  • CONCLUSION: The MMR status or p53 positivity was not significantly associated with outcomes to FOLFOX as adjuvant chemotherapy in colon cancer patients with R0 resection.
  • Adding oxaliplatin in adjuvant chemotherapy may overcome negative impact of 5-FU on colon cancers with MSI-H/MMR-D.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Colonic Neoplasms / genetics. Microsatellite Instability / drug effects

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20033812.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Organoplatinum Compounds; 0 / Tumor Suppressor Protein p53; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


13. Dahlqvist C, Fremault A, Carrasco J, Colinet B: [Obliterative bronchiolitis with organising pneumonia following FOLFOX 4 chemotherapy]. Rev Mal Respir; 2010;27(1):84-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Bronchiolite oblitérante avec pneumonie organisée après chimiothérapie de type FOLFOX 4.
  • INTRODUCTION: FOLFOX 4 chemotherapy (5-fluorouracil, leucovorin and oxaliplatin) is the standard adjuvant treatment for stage III colon cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / toxicity. Colonic Neoplasms / drug therapy. Cryptogenic Organizing Pneumonia / chemically induced

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20146958.001).
  • [ISSN] 1776-2588
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


1
Advertisement
4. Brosens RP, Oomen JL, Glas AS, van Bochove A, Cuesta MA, Engel AF: POSSUM predicts decreased overall survival in curative resection for colorectal cancer. Dis Colon Rectum; 2006 Jun;49(6):825-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 542 patients survived a radical resection for Stages I, II, or III colorectal cancer.
  • Differences in overall survival also were found when patients in Stages I, II, and III were analyzed separately.
  • Risk factors for overall survival were advanced stage of disease, poor tumor differentiation, mucinous adenocarcinoma, older than age 70 years, and poor condition of the patient at time of operation.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Colorectal Neoplasms / mortality. Colorectal Neoplasms / surgery. Severity of Illness Index

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550320.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Yamada K, Ogata S, Saiki Y, Fukunaga M, Tsuji Y, Takano M: Long-term results of intersphincteric resection for low rectal cancer. Dis Colon Rectum; 2009 Jun;52(6):1065-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The five-year disease-free survival rates classified according to the TNM stage were 100 percent for stage I, 83.5 percent for stage II, and 72.0 percent for stage III cases.
  • [MeSH-major] Adenocarcinoma / surgery. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581848.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Min BS, Kim NK, Ko YT, Baek SH, Lee KY, Sohn SK, Cho CH, Kang DR: Clinicopathological features of signet-ring cell carcinoma of the colon and rectum: a case-matched study. Hepatogastroenterology; 2009 Jul-Aug;56(93):984-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of signet-ring cell carcinoma of the colon and rectum: a case-matched study.
  • BACKGROUND/AIMS: Primary colorectal signet-ring cell carcinoma (SRC) is a rare type of mucin-containing adenocarcinoma and little information exists about its clinicopathological features.
  • METHODS: The clinicopathological features of 27 patients with primary colorectal SRC were compared with non-signet-ring cell mucinous carcinoma (MC) and non-mucinous adenocarcinoma (NMC).
  • In stage II and III, SRC was found to be associated with a worse cancer-specific survival and a higher systemic recurrence rates than either NMC or MC.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Colorectal Neoplasms / pathology


17. Grabowski P, Sturm I, Schelwies K, Maaser K, Buhr HJ, Dörken B, Zeitz M, Daniel PT, Scherübl H: Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis. Int J Colorectal Dis; 2006 Apr;21(3):221-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis.
  • Moreover, an altered p53/BAX pathway is associated with a poor clinical outcome in Union Internationale Contre le Cancer (UICC) stage III disease.
  • PATIENTS AND METHODS: Specimens were analyzed from 59 patients with UICC stage III disease who underwent surgery for colorectal adenocarcinoma at our institution and were followed up for 5 years or until death.
  • RESULTS: p53 status/BAX expression and neuroendocrine differentiation are not correlated in stage III colorectal cancers.
  • Both represent independent prognostic markers in UICC stage III disease.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 1994 Sep 15;733:46-55 [7978895.001]
  • [Cites] Leukemia. 2001 Jul;15(7):1022-32 [11455969.001]
  • [Cites] Int J Cancer. 2000 Aug 15;87(4):517-21 [10918191.001]
  • [Cites] Acta Oncol. 1993;32(2):115-24 [8323752.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3205-9 [12374690.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2035-44 [11187890.001]
  • [Cites] Essays Biochem. 2003;39:73-88 [14585075.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Int J Cancer. 2000 Oct 15;88(2):281-6 [11004681.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):651-8 [11237386.001]
  • [Cites] Int J Cancer. 2002 Jun 1;99(4):589-96 [11992551.001]
  • [Cites] J Clin Pathol. 1995 Aug;48(8):754-8 [7560204.001]
  • [Cites] Virchows Arch. 2002 Sep;441(3):256-63 [12242522.001]
  • [Cites] Ann Surg Oncol. 1996 Nov;3(6):574-9 [8915491.001]
  • [Cites] Int J Cancer. 1993 Jul 9;54(5):765-71 [8100808.001]
  • [Cites] Br J Cancer. 1999 Jan;79(2):191-203 [9888457.001]
  • [Cites] Cell. 1997 Nov 14;91(4):479-89 [9390557.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1859-61 [2004298.001]
  • [Cites] Oncogene. 2001 May 17;20(22):2749-60 [11420687.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2272-81 [11304781.001]
  • [Cites] Anticancer Res. 2001 Jan-Feb;21(1A):253-9 [11299743.001]
  • [Cites] Expert Opin Investig Drugs. 2001 Jun;10(6):1011-9 [11772231.001]
  • [Cites] Gut. 2004 Jun;53(6):899-910 [15138220.001]
  • [Cites] Endocr Rev. 2003 Aug;24(4):389-427 [12920149.001]
  • [Cites] APMIS. 2004 Jan;112(1):49-56 [14961975.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 Apr;13(4):405-11 [11338071.001]
  • [Cites] Cell. 1995 Jan 27;80(2):293-9 [7834749.001]
  • [Cites] Int J Cancer. 2002 Feb 1;97(4):403-9 [11802199.001]
  • [Cites] World J Surg. 2002 Jan;26(1):59-66 [11898035.001]
  • [Cites] Cancer. 1992 Jun 1;69(11):2641-6 [1571893.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):523-33 [11330579.001]
  • [Cites] Eur J Clin Invest. 1998 Dec;28(12):1038-49 [9893017.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1364-74 [10334520.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1766-75 [14583782.001]
  • [Cites] Physiol Rev. 1988 Apr;68(2):456-502 [3282244.001]
  • [Cites] Digestion. 2000;62 Suppl 1:3-18 [10940682.001]
  • [Cites] J Biol Chem. 2004 Jan 16;279(3):1713-9 [14593113.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):445-54 [12478659.001]
  • [Cites] Int J Cancer. 1995 Mar 3;60(5):645-51 [7860139.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4573-81 [10969809.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;64(5):293-6 [8287125.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27643-50 [12011069.001]
  • [Cites] Histopathology. 1998 Feb;32(2):133-8 [9543669.001]
  • [Cites] Arch Pathol Lab Med. 2001 Jan;125(1):91-8 [11151060.001]
  • [Cites] Arch Pathol Lab Med. 1998 Oct;122(10):912-4 [9786353.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1448-53 [9326914.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3391-401 [12885834.001]
  • (PMID = 16485142.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / bcl-2-Associated X Protein
  •  go-up   go-down


18. Liang JT, Lai HS, Lee PH: Multimedia article. Laparoscopic abdominoperineal resection for lower rectal cancers: how do we do it? Surg Endosc; 2006 Apr;20(4):695-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The appropriateness of the laparoscopic approach for the resection of rectal cancer has been controversial, although it is well established in colon cancer.
  • METHODS: Patients with lower rectal adenocarcinoma located within 6 cm above the anal verge were recruited and subjected to laparoscopic APR.
  • Physical status (American Society of Anesthesiology classification) was class I in 12, class II in eight, and class III in two patients.
  • Two patients were in pathologic TNM stage I, 14 in stage II, and six in stage III.
  • [MeSH-major] Abdomen / surgery. Adenocarcinoma / surgery. Laparoscopy / methods. Perineum / surgery. Rectal Neoplasms / surgery

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1481-5 [12432295.001]
  • [Cites] World J Surg. 2002 Mar;26(3):377-83 [11865378.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):46-54; discussion 54-5 [9660024.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2000 Feb;10(1):47-53 [10706303.001]
  • [Cites] World J Surg. 2003 Feb;27(2):190-6 [12616435.001]
  • [Cites] Ann Surg. 1967 Sep;166(3):420-7 [6039601.001]
  • (PMID = 16502195.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Video-Audio Media
  • [Publication-country] Germany
  •  go-up   go-down


19. Yokoi K, Tanaka N, Furukawa K, Seya T, Ohaki Y, Tajiri T: Case of adenosquamous carcinoma of the ascending colon. J Nippon Med Sch; 2008 Aug;75(4):242-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of adenosquamous carcinoma of the ascending colon.
  • Adenocarcinoma accounts for most of the malignant tumors originating from the colon, whereas adenosquamous carcinoma is rare, accounting for about 0.1% of all colon cancers.
  • We present herein a case of adenosquamous carcinoma of the ascending colon.
  • A barium enema examination and lower gastrointestinal endoscopy showed a type 3 tumor in the ascending colon, and a biopsy confirmed the diagnosis of adenosquamous carcinoma.
  • Right hemicolectomy was performed, and the tumor was diagnosed as a stage III advanced colon cancer.
  • A search of Japanese literature over the past 25 years yielded 70 patients with adenosquamous carcinoma of the colon, and the clinicopathological features are discussed herein.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18781050.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Li M, Li JY, Zhao AL, He JS, Zhou LX, Li YA, Gu J: Survival stratification panel of colorectal carcinoma with combined expression of carcinoembryonic antigen, matrix metalloproteinases-2, and p27 kip1. Dis Colon Rectum; 2007 Nov;50(11):1887-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The prognosis varies greatly in colorectal carcinoma patients, even in the same stage.
  • In different stages, coexpression tumor markers functioned in Stages II and III but not in the 19 cases of Stage I.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / nursing. Carcinoembryonic Antigen / metabolism. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / mortality. Intracellular Signaling Peptides and Proteins / metabolism. Matrix Metalloproteinase 2 / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882488.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / Carcinoembryonic Antigen; 0 / Intracellular Signaling Peptides and Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


26. Mammen JM, James LE, Molloy M, Williams A, Wray CJ, Sussman JJ: The relationship of lymph node dissection and colon cancer survival in the Veterans Affairs Central Cancer Registry. Am J Surg; 2007 Sep;194(3):349-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship of lymph node dissection and colon cancer survival in the Veterans Affairs Central Cancer Registry.
  • BACKGROUND: The extent of lymphadenectomy in colon cancer may impact potential to cure and accuracy of staging.
  • METHODS: The Veterans Affairs Central Cancer Registry database was queried for TNM stage I-III colon adenocarcinoma patients and yielded 5,823 individuals.
  • RESULTS: The overall survival (OS) in stage II patients was greater with the higher number of lymph node (LN) examined.
  • For stage II patients, the 5-year OS was 34%, 43%, 47%, and 55% for the lowest to highest quartiles (P = .007).
  • For stage III patients, the 5-year OS was 31%, 27%, 38%, and 53% for the lowest to highest quartiles (not significant overall).
  • CONCLUSIONS: More extensive lymphadenectomy is associated with improved OS in stage II colon cancer patients.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Colonic Neoplasms / mortality. Colonic Neoplasms / surgery. Lymph Node Excision

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17693281.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Gibson TB, Ranganathan A, Grothey A: Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer; 2006 May;6(1):29-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer.
  • The results of a phase III trial which compared panitumumab as a single agent to best supportive care in patients with previously treated metastatic CRC have recently been reported Pantitumumab therapy resulted in a 46% reduction in the risk of tumor progression and a partial response rate of 8%.
  • Further clinical studies re ongoing and planned to test panitumumab in combination with chemotherapy in first-line therapy of advanced-stage CRC and adjuvant treatment of colon cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antibodies, Monoclonal / therapeutic use. Colorectal Neoplasms / pathology


28. Niedzielska I, Niedzielski Z, Tkacz M, Orawczyk T, Ziaja K, Starzewski J, Mazurek U, Markowski J: Toll-like receptors and the tendency of normal mucous membrane to transform to polyp or colorectal cancer. J Physiol Pharmacol; 2009 May;60 Suppl 1:65-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixteen HG-U133A oligonucleotide microarrays were analysed including four of colonic polyps, four of adenocarcinoma with different degree of histological differentiation (2 poorly and 2 highly differentiated), and eight of macroscopically normal tissue.
  • An analysis of all per cent variability values with regard to malignancy stage increasing from polyp to stages I to III adenocarcinoma, and normal colon mucosa shows a statistically significant relationship for TLR2 (increasing) and TLR3 (decreasing).
  • In normal colon mucosa of polyposis patients the highest mRNA copy numbers were observed for TLR3, and the lowest for TLR7.
  • TLR3 may serve as a marker of colon tissue metaplasia and may indicate the tendency of normal tissue to form polyps transforming to colorectal cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Colonic Polyps / metabolism. Colorectal Neoplasms / metabolism. Mucous Membrane / metabolism. Toll-Like Receptors / biosynthesis
  • [MeSH-minor] Adult. Aged. Colon / metabolism. Colon / pathology. Female. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. RNA, Messenger / biosynthesis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19609015.001).
  • [ISSN] 1899-1505
  • [Journal-full-title] Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • [ISO-abbreviation] J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Toll-Like Receptors
  •  go-up   go-down


29. Nosho K, Shima K, Irahara N, Kure S, Firestein R, Baba Y, Toyoda S, Chen L, Hazra A, Giovannucci EL, Fuchs CS, Ogino S: SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol; 2009 Jul;22(7):922-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The class III histone deacetylase SIRT1 (sir2) is important in epigenetic gene silencing.
  • SIRT1 was not significantly related with age, sex, tumor location, stage, signet ring cells, cyclooxygenase-2 (COX-2), LINE-1 hypomethylation, KRAS, BRAF, BMI, PIK3CA, HDAC, p53, beta-catenin, COX-2, or patient prognosis.
  • In conclusion, SIRT1 expression is associated with CIMP-high MSI-high colon cancer, suggesting involvement of SIRT1 in gene silencing in this unique tumor subtype.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS One. 2008;3(4):e2020 [18414679.001]
  • [Cites] Int J Cancer. 2008 Jun 15;122(12):2767-73 [18366060.001]
  • [Cites] Neoplasia. 2008 Jun;10(6):534-41 [18516290.001]
  • [Cites] Cancer Lett. 2008 Sep 18;268(2):177-86 [18471961.001]
  • [Cites] PLoS One. 2008;3(11):e3698 [19002263.001]
  • [Cites] Mod Pathol. 2008 Dec;21(12):1533-41 [18849918.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 3;100(23):1734-8 [19033568.001]
  • [Cites] J Clin Oncol. 2008 Dec 10;26(35):5713-20 [18955444.001]
  • [Cites] Mod Pathol. 2008 Nov;21(11):1403-12 [18587323.001]
  • [Cites] Gut. 2009 Jan;58(1):90-6 [18832519.001]
  • [Cites] Mod Pathol. 2009 Jan;22(1):151-60 [19011600.001]
  • [Cites] Science. 2004 Jul 16;305(5682):390-2 [15205477.001]
  • [Cites] Stat Med. 1989 May;8(5):551-61 [2657958.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] Science. 2004 Dec 17;306(5704):2105-8 [15604409.001]
  • [Cites] Cell. 2005 Feb 25;120(4):473-82 [15734680.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):388-96 [15864280.001]
  • [Cites] J Mol Diagn. 2005 Aug;7(3):413-21 [16049314.001]
  • [Cites] Gastroenterology. 2005 Sep;129(3):837-45 [16143123.001]
  • [Cites] Gastroenterology. 2005 Sep;129(3):1121-4 [16143149.001]
  • [Cites] Cell. 2005 Nov 4;123(3):437-48 [16269335.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):59-68 [16118624.001]
  • [Cites] PLoS Genet. 2006 Mar;2(3):e40 [16596166.001]
  • [Cites] Nat Genet. 2006 May;38(5):566-9 [16642021.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):209-17 [16645207.001]
  • [Cites] PLoS Genet. 2005 Dec;1(6):e77 [16362078.001]
  • [Cites] Gut. 2006 Jul;55(7):1000-6 [16407376.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] J Mol Diagn. 2006 Nov;8(5):582-8 [17065427.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):15-22 [17086168.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):375-83 [17277760.001]
  • [Cites] Nucleic Acids Res. 2000 Apr 15;28(8):E32 [10734209.001]
  • [Cites] Genes Dev. 2000 May 1;14(9):1021-6 [10809662.001]
  • [Cites] Nature. 2000 Nov 9;408(6809):255-62 [11089983.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • [Cites] EMBO J. 2002 May 15;21(10):2383-96 [12006491.001]
  • [Cites] Nat Genet. 2002 Nov;32(3):378-83 [12379856.001]
  • [Cites] Nat Genet. 2002 Nov;32(3):370-7 [12410229.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6011-4 [12414620.001]
  • [Cites] Nucleic Acids Res. 2004;32(3):e38 [14973332.001]
  • [Cites] Cell. 2004 Feb 20;116(4):551-63 [14980222.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):331-8 [17277767.001]
  • [Cites] Nat Rev Genet. 2007 Apr;8(4):286-98 [17339880.001]
  • [Cites] Biochem J. 2007 May 15;404(1):1-13 [17447894.001]
  • [Cites] Cancer J. 2007 Jan-Feb;13(1):49-55 [17464246.001]
  • [Cites] N Engl J Med. 2007 May 24;356(21):2131-42 [17522398.001]
  • [Cites] J Mol Diagn. 2007 Jul;9(3):305-14 [17591929.001]
  • [Cites] Neoplasia. 2007 Jul;9(7):569-77 [17710160.001]
  • [Cites] Gut. 2007 Nov;56(11):1498-500 [17938428.001]
  • [Cites] Mod Pathol. 2007 Nov;20(11):1183-90 [17873897.001]
  • [Cites] Nat Rev Genet. 2007 Nov;8(11):829-33 [17909537.001]
  • [Cites] Nat Rev Genet. 2007 Nov;8(11):835-44 [17909538.001]
  • [Cites] Biotechnol J. 2007 Nov;2(11):1360-8 [17806102.001]
  • [Cites] J Mol Diagn. 2008 Jan;10(1):13-27 [18165277.001]
  • [Cites] Carcinogenesis. 2008 Feb;29(2):434-9 [18048385.001]
  • [Cites] Epigenetics. 2008 Jan-Feb;3(1):28-37 [18326939.001]
  • [Cites] Mod Pathol. 2008 May;21 Suppl 2:S23-30 [18437170.001]
  • (PMID = 19430421.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K07 CA122826-02; United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CA / P01 CA055075; United States / NCI NIH HHS / CA / CA122826-02; United States / NCI NIH HHS / CA / K07 CA122826; United States / NCI NIH HHS / CA / CA055075-15; United States / NCI NIH HHS / CA / P50 CA127003-02; United States / NCI NIH HHS / CA / P01 CA87969; United States / NCI NIH HHS / CA / P01 CA55075; United States / NCI NIH HHS / CA / P01 CA087969-09; United States / NCI NIH HHS / CA / P50 CA127003; United States / NCI NIH HHS / CA / P01 CA055075-15
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.3.1.85 / Fatty Acid Synthases; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins
  • [Other-IDs] NLM/ NIHMS100427; NLM/ PMC2704253
  •  go-up   go-down


30. Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K: Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer; 2006;5:62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The involvement of the cyclooxygenases (COX), in particular COX-2, is well documented for many tumours, e.g. colon, breast and prostate cancer, by both experimental and clinical studies.
  • The increase of COX-2 was also correlated to stage (FIGO classification) with significant elevations in stages II and III.
  • EP1 was increased in stage III while no significant alterations were demonstrated for COX-1, mPGES-1 or EP2 for stage.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cyclooxygenase 1 / metabolism. Cyclooxygenase 2 / metabolism. Densitometry. Disease Progression. Epithelial Cells / pathology. Female. Humans. Immunoblotting. Immunohistochemistry. Intramolecular Oxidoreductases / metabolism. Neoplasm Staging. Ovary / metabolism. Receptors, Prostaglandin E / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Soc Gynecol Investig. 2002 May-Jun;9(3):168-73 [12009392.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2002;21(2):149-53 [12086401.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1205-11 [12181243.001]
  • [Cites] J Reprod Immunol. 2002 Oct-Nov;57(1-2):47-60 [12385833.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):906-11 [12615701.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1423-9 [14508829.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1298-304 [14520463.001]
  • [Cites] Prog Lipid Res. 2004 Jan;43(1):3-35 [14636669.001]
  • [Cites] Oncogene. 2003 Nov 27;22(54):8653-61 [14647459.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2607-23 [14669280.001]
  • [Cites] Oncol Rep. 2004 Feb;11(2):309-13 [14719060.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):538-45 [14760075.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):622-7 [14766256.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4670-9 [15269139.001]
  • [Cites] Acta Obstet Gynecol Scand. 2004 Sep;83(9):783-95 [15315588.001]
  • [Cites] Reproduction. 2004 Nov;128(5):607-14 [15509706.001]
  • [Cites] Lancet. 1971 Jul 17;2(7716):163 [4104488.001]
  • [Cites] Gynecol Oncol. 1983 Dec;16(3):340-5 [6360817.001]
  • [Cites] Gynecol Obstet Invest. 1984;18(5):225-9 [6396175.001]
  • [Cites] Prostaglandins. 1985 May;29(5):665-72 [3859890.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):275-80 [9221804.001]
  • [Cites] J Histochem Cytochem. 1998 Jan;46(1):77-84 [9405496.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1240-8 [10098766.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10501-6 [10468638.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67 [10469746.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1927-33 [15870720.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 Aug;73(2):103-11 [15963707.001]
  • [Cites] Oncogene. 2005 Dec 1;24(54):7991-8002 [16044148.001]
  • [Cites] Nucleic Acids Res. 2006;34(1):217-31 [16397300.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1884-91 [16287068.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):130-40 [16491072.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2527-31 [16510568.001]
  • [Cites] Curr Pharm Des. 2006;12(8):943-54 [16533161.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Am J Obstet Gynecol. 2005 Mar;192(3):819-25 [15746677.001]
  • [Cites] Oncol Rep. 2005 Apr;13(4):559-83 [15756426.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2234-42 [15781636.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3735-44 [15867369.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3250-6 [15867220.001]
  • [Cites] J Reprod Fertil. 2000 Mar;118(2):375-85 [10864803.001]
  • [Cites] Epidemiology. 2000 Mar;11(2):111-7 [11021606.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):849-53 [11238034.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:661-90 [11264472.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2328-34 [11280806.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Int J Mol Med. 2001 Jul;8(1):31-6 [11408945.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2496-504 [11489832.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1048-51 [11533709.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7305-9 [11585770.001]
  • [Cites] Int J Mol Med. 2001 Dec;8(6):603-6 [11712072.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):202-9 [11801560.001]
  • [Cites] Annu Rev Physiol. 2002;64:69-92 [11826264.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):893-903 [11891188.001]
  • (PMID = 17107625.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Prostaglandin E; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.3 / prostaglandin-E synthase; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC1657027
  •  go-up   go-down


31. Habr-Gama A, Perez RO, Nadalin W, Nahas SC, Ribeiro U Jr, Silva E Sousa AH Jr, Campos FG, Kiss DR, Gama-Rodrigues J: Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. J Gastrointest Surg; 2005 Jan;9(1):90-9; discussion 99-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
  • The purpose of the present study was to determine the correlation between final stage and survival in these patients regardless of initial disease stage.
  • Two hundred sixty patients with distal (0-7 cm from anal verge) rectal adenocarcinoma considered resectable were treated by neoadjuvant CRT with 5-FU and leucovorin plus 5040 cGy.
  • Overall survival and disease-free survival were compared according to Kaplan-Meier curves and log-rank tests according to final stage.
  • Seventy-one patients (28%) showed complete clinical response (clinical stage 0).
  • In 22 of these patients (9%), pathologic examination revealed pT0 N0 M0 (stage p0), 59 patients (22%) had stage I, 68 patients (26%) had stage II, and 40 patients (15%) had stage III disease.
  • Overall survival rates were significantly higher in stage c0 (P=0.01) compared with stage p0.
  • Disease-free survival rate showed better results in stage c0, but the results were not significant.
  • Five-year overall and disease-free survival rates were 97.7% and 84% (stage 0); 94% and 74% (stage I); 83% and 50% (stage II); and 56% and 28% (stage III), respectively.
  • Also, stage 0 is significantly associated with improved outcome.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Neoadjuvant Therapy. Rectal Neoplasms / mortality. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1993 Feb 20;341(8843):457-60 [8094488.001]
  • [Cites] Br J Surg. 2003 Aug;90(8):999-1003 [12905555.001]
  • [Cites] J Gastrointest Surg. 2004 Jan;8(1):56-62; discussion 62-3 [14746836.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1027-38 [10421535.001]
  • [Cites] Eur J Surg Oncol. 2001 Jun;27(4):349-53 [11417978.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Rev Invest Clin. 2001 Sep-Oct;53(5):388-95 [11795103.001]
  • [Cites] J Natl Cancer Inst. 1988 Mar 2;80(1):21-9 [3276900.001]
  • [Cites] Rev Invest Clin. 2001 Jan-Feb;53(1):65-76 [11332053.001]
  • [Cites] Br J Surg. 2001 Jul;88(7):988-93 [11442533.001]
  • [Cites] World J Surg. 2001 Aug;25(8):1006-11 [11571965.001]
  • [Cites] Br J Surg. 1986 Sep;73(9):732-5 [3756437.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):1121-30 [11920483.001]
  • [Cites] Lancet. 1986 Jun 28;1(8496):1479-82 [2425199.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):935-41 [9869213.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1417-24 [7751887.001]
  • [Cites] Dis Colon Rectum. 1997 May;40(5):515-22 [9152176.001]
  • [Cites] Dis Colon Rectum. 2001 Aug;44(8):1123-8 [11535851.001]
  • [Cites] Dis Colon Rectum. 2000 Dec;43(12):1695-1701; discussion 1701-3 [11156453.001]
  • [Cites] Radiother Oncol. 1999 May;51(2):153-60 [10435807.001]
  • [Cites] J Surg Oncol. 2003 Jul;83(3):133-9 [12827680.001]
  • [Cites] Arch Surg. 2002 Feb;137(2):206-10 [11822961.001]
  • [Cites] Cancer. 1994 Feb 1;73(3):563-9 [7507795.001]
  • [Cites] J Am Coll Surg. 2002 Feb;194(2):131-5; discussion 135-6 [11848629.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):279-86 [14991488.001]
  • [Cites] Dis Colon Rectum. 1998 Sep;41(9):1087-96 [9749491.001]
  • [Cites] J Pathol. 1994 Feb;172(2):183-7 [7513353.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):21-7 [9588913.001]
  • [Cites] Dis Colon Rectum. 1997 Feb;40(2):131-9 [9075745.001]
  • (PMID = 15623449.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


32. Tsigkou A, Marrelli D, Reis FM, Luisi S, Silva-Filho AL, Roviello F, Triginelli SA, Petraglia F: Total inhibin is a potential serum marker for epithelial ovarian cancer. J Clin Endocrinol Metab; 2007 Jul;92(7):2526-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1) epithelial ovarian cancer, stage II-III (n = 89);.
  • 3) breast (n = 10), colon (n = 10), and stomach (n = 10) cancers; and 4) controls (n = 95).
  • In four cases of women with stage IIC mucinous tumor, blood specimens were collected during the follow-up time.
  • [MeSH-major] Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / diagnosis. Biomarkers, Tumor / blood. Immunoenzyme Techniques / methods. Inhibins / blood. Ovarian Neoplasms / blood. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / diagnosis. Aged. Aged, 80 and over. CA-125 Antigen / blood. Cross-Sectional Studies. Epithelium / pathology. Female. Humans. Middle Aged. ROC Curve

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17473066.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 57285-09-3 / Inhibins
  •  go-up   go-down


33. Rego RL, Foster NR, Smyrk TC, Le M, O'Connell MJ, Sargent DJ, Windschitl H, Sinicrope FA: Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer; 2010 Jan 5;102(1):165-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status.
  • BACKGROUND: Evidence suggests that epidermal growth factor receptor (EGFR)-activation status may better predict the clinical behaviour of colon cancers than does EGFR expression.
  • However, the prognostic effect of phospho-EGFR in primary colon cancer remains undefined.
  • METHODS: Phospho-EGFR (Tyr-1173) and EGFR expression were analysed by immunohistochemistry (IHC) in tissue microarrays of TNM stage II and III colon cancers from completed adjuvant therapy trials (n=388).
  • Although phospho-EGFR was unrelated to clinicopathological variables, strong EGFR intensity was associated with higher tumour stage (P=0.03).
  • Stage and lymph node number were prognostic for DFS and OS, and histological grade for OS.
  • EGFR was an independent predictor of DFS (P=0.042) after adjustment for stage, histological grade, age, and MMR status.

  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1572-82 [15117979.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(21):7875-86 [14560030.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6487-501 [15475436.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5849-52 [8261392.001]
  • [Cites] J Biol Chem. 1994 Jul 15;269(28):18674-8 [8034616.001]
  • [Cites] Eur J Surg Oncol. 1995 Jun;21(3):269-75 [7781795.001]
  • [Cites] Biochemistry. 1995 Dec 19;34(50):16456-66 [8845374.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):669-74 [8608874.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1713-8 [9563488.001]
  • [Cites] Clin Cancer Res. 1995 Jan;1(1):19-31 [9815883.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1295-303 [10433618.001]
  • [Cites] J Biol Chem. 1999 Sep 10;274(37):26091-7 [10473558.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):102-8 [15598946.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1803-10 [15677699.001]
  • [Cites] Int J Oncol. 2005 Aug;27(2):317-25 [16010411.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1350-6 [15832190.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S59-62 [16399434.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1169-77 [16505437.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2834-43 [16510606.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2738-44 [16675565.001]
  • [Cites] Clin Colorectal Cancer. 2006 Jul;6(2):133-9 [16945169.001]
  • [Cites] Gastroenterology. 2006 Sep;131(3):729-37 [16952542.001]
  • [Cites] Br J Cancer. 2006 Dec 4;95(11):1525-8 [17088913.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1232-8 [17187355.001]
  • [Cites] Lung Cancer. 2007 Mar;55(3):349-55 [17161498.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1658-64 [17470858.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2184-90 [17538163.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3597-604 [17575224.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4405-13 [17906204.001]
  • [Cites] Ann Oncol. 2008 Dec;19(12):2033-8 [18632722.001]
  • [Cites] Pathology. 2009;41(4):356-60 [19404848.001]
  • [Cites] Curr Opin Oncol. 2009 Jul;21(4):369-73 [19444104.001]
  • [Cites] Clin Cancer Res. 2009 Jul 15;15(14):4531-7 [19584170.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2225-31 [10786688.001]
  • [Cites] Int J Cancer. 2000 Oct 1;88(1):77-81 [10964085.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1521-6 [11818567.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1735-43 [11919229.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098.001]
  • [Cites] Eur J Cancer. 2002 May;38(8):1065-71 [12008194.001]
  • [Cites] Eur J Cancer. 2002 Nov;38(17):2258-64 [12441262.001]
  • [Cites] Eur J Cancer. 2003 Jul;39(10):1348-54 [12826036.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Virchows Arch. 2003 Aug;443(2):115-21 [12802583.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3069-75 [15131045.001]
  • (PMID = 19997103.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK084567; United States / NCI NIH HHS / CA / R01 CA104683; United States / NCI NIH HHS / CA / CA 104683
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 21820-51-9 / Phosphotyrosine; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2813748
  •  go-up   go-down


34. Fang YJ, Lu ZH, Wang F, Wu XJ, Li LR, Zhang LY, Pan ZZ, Wan DS: Prognostic impact of ERβ and MMP7 expression on overall survival in colon cancer. Tumour Biol; 2010 Dec;31(6):651-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of ERβ and MMP7 expression on overall survival in colon cancer.
  • Estrogen receptor beta (ERβ) is the most highly expressed protein in patients with colon cancer.
  • We have previously shown that endocrine therapy can inhibit MMP7 expression in colon cancer cells.
  • In this study, we aim to identify the prognostic effects and correlation of ERβ and MMP7 in the context of colon cancer.
  • ERβ and MMP7 levels were assessed by immunohistochemistry in normal mucosa and tumoral tissues from 423 patients with stage I-III colon cancer.
  • In the subset of patients with high expression levels of tumoral nuclear ERβ, high expression of MMP7 was related to OS and CSS among colon cancer patients with high expression of ERβ.
  • In conclusion, our results suggest that low expression of ERβ was a risk factor in colon cancer, and high expression of MMP7 was an independent prognostic factor of ERβ-positive patients with colon cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Colonic Neoplasms / metabolism. Colonic Neoplasms / mortality. Estrogen Receptor beta / metabolism. Matrix Metalloproteinase 7 / metabolism

  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2001 Jun;233(6):786-92 [11371737.001]
  • [Cites] J Invest Dermatol. 1995 Aug;105(2):190-6 [7636300.001]
  • [Cites] Eur J Cancer. 2003 Jun;39(9):1251-8 [12763213.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Dec;82(12):4258-65 [9398750.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5925-30 [8650195.001]
  • [Cites] Hum Pathol. 2001 Sep;32(9):940-4 [11567223.001]
  • [Cites] N Engl J Med. 2004 Mar 4;350(10):991-1004 [14999111.001]
  • [Cites] Oncol Rep. 2005 Jul;14(1):17-21 [15944762.001]
  • [Cites] Endocr Relat Cancer. 2004 Sep;11(3):537-51 [15369453.001]
  • [Cites] J Exp Clin Cancer Res. 2009 Sep 29;28:132 [19785773.001]
  • [Cites] JAMA. 2002 Jul 17;288(3):321-33 [12117397.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):455-69 [15947116.001]
  • [Cites] Cancer. 2000 May 15;88(10):2398-424 [10820364.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Dig Dis Sci. 2002 Dec;47(12):2720-8 [12498292.001]
  • [Cites] Cell Oncol. 2009;31(3):235-47 [19478391.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):245-8 [10667568.001]
  • [Cites] Int J Colorectal Dis. 2009 Aug;24(8):875-84 [19421758.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2959-64 [16477031.001]
  • [Cites] J Pathol. 2005 Sep;207(1):53-60 [15954165.001]
  • (PMID = 20680712.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogen Receptor beta; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


35. Liang JT, Huang KC, Lai HS, Lee PH, Sun CT: Oncologic results of laparoscopic D3 lymphadenectomy for male sigmoid and upper rectal cancer with clinically positive lymph nodes. Ann Surg Oncol; 2007 Jul;14(7):1980-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study subjects were tumor, node, metastasis system stage III rectosigmoid cancer staged by clinical images.
  • The extent of D3 dissection and the postoperative lymph node mapping were according to the guidelines of the Japanese Society for Cancer of the Colon and Rectum.
  • CONCLUSIONS: The good short-term oncologic results and quick convalescence mean that the laparoscopic D3 dissection may be recommended for patients with stage III rectosigmoid cancer who could accept the genitourinary dysfunction.
  • [MeSH-major] Adenocarcinoma / surgery. Lymph Node Excision / methods. Rectal Neoplasms / surgery. Sigmoid Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17458586.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Asaad SM, Jubelirer SJ, Welch CA: Prognostic indicators for stage II (Dukes' stage B) adenocarcinoma of the colon. W V Med J; 2005 Sep-Oct;101(5):210-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic indicators for stage II (Dukes' stage B) adenocarcinoma of the colon.
  • To determine the prognostic indicators that are associated with lower disease free survival (DFS) and overall survival (OS) in stage II colon cancer patients, the tumor registry records were reviewed for all patients diagnosed with stage II and III adenocarcinoma of the colon at Charleston Area Medical Center from 1986 to 1994.
  • The prognostic indicators of 174 stage II patients who had not undergone treatment were assessed for DFS and OS.
  • In addition, DFS and OS curves for stage II patients with < 7 LNR were not significantly different from survival curves for stage III patients.
  • Treatment decisions are made based primarily on stage, and stage II patients are not routinely offered adjuvant therapy.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Neoplasm Staging. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16422269.001).
  • [ISSN] 0043-3284
  • [Journal-full-title] The West Virginia medical journal
  • [ISO-abbreviation] W V Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Carson HJ, Krivit JS, Eilers SG: Metastasis of colonic adenocarcinoma to the external ear canal: an unusual case with a complex-pattern of disease progression. Ear Nose Throat J; 2005 Jan;84(1):36-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of colonic adenocarcinoma to the external ear canal: an unusual case with a complex-pattern of disease progression.
  • We report on a patient who developed far-ranging metastases of adenocarcinoma of the colon that followed a gradual cephalad progression, including the right external ear canal, and led to hearing loss.
  • The patient was a 63-year-old white male with stage III adenocarcinoma of the colon.
  • Physical examination of the head and neck showed a mass in the external ear canal, and biopsy confirmed adenocarcinoma.
  • The significance of such wide-ranging metastases is that metastasis of adenocarcinoma to the ear did not signal imminent death, and relief of the hearing loss it caused was possible.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Ear Canal. Ear Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15742771.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Wick MR, Vitsky JL, Ritter JH, Swanson PE, Mills SE: Sporadic medullary carcinoma of the colon: a clinicopathologic comparison with nonhereditary poorly differentiated enteric-type adenocarcinoma and neuroendocrine colorectal carcinoma. Am J Clin Pathol; 2005 Jan;123(1):56-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic medullary carcinoma of the colon: a clinicopathologic comparison with nonhereditary poorly differentiated enteric-type adenocarcinoma and neuroendocrine colorectal carcinoma.
  • We studied 68 sporadic colorectal carcinomas (CRCs) with medullary features (MCRCs) and compared them with 35 poorly differentiated purely "enteric" CRCs (ECRCs) and 15 purely neuroendocrine carcinomas (NECs) of grades II and III, all in patients lacking a family history of CRC.
  • MCRCs were significantly more common in the ascending colon than were ECRCs, but there was no significant dissimilarity to NECs.
  • Despite an infiltrative growth pattern, MCRC was less likely than ECRC to manifest with stage III or IV disease, but there was no stage-related difference from NECs.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Medullary / pathology. Carcinoma, Neuroendocrine / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15762280.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Billingsley KG, Morris AM, Dominitz JA, Matthews B, Dobie S, Barlow W, Wright GE, Baldwin LM: Surgeon and hospital characteristics as predictors of major adverse outcomes following colon cancer surgery: understanding the volume-outcome relationship. Arch Surg; 2007 Jan;142(1):23-31; discussion 32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgeon and hospital characteristics as predictors of major adverse outcomes following colon cancer surgery: understanding the volume-outcome relationship.
  • PATIENTS: Patients aged 66 years and older, diagnosed and surgically treated for stage I, II, or III colon cancer between 1992 and 1996 (n = 22 672).
  • [MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Digestive System Surgical Procedures / utilization. Hospitals / utilization. Outcome Assessment (Health Care)

  • MedlinePlus Health Information. consumer health - Health Facilities.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17224497.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Yano H, Saito Y, Kirihara Y, Takashima J: Tumor invasion of lymph node capsules in patients with Dukes C colorectal adenocarcinoma. Dis Colon Rectum; 2006 Dec;49(12):1867-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor invasion of lymph node capsules in patients with Dukes C colorectal adenocarcinoma.
  • METHODS: We analyzed 480 positive lymph nodes from 155 consecutive patients with Stage III colorectal cancer to determine the frequency and significance of lymph node capsular invasion.
  • CONCLUSIONS: Lymph node capsular invasion, determined by routine hematoxylin-eosin staining, is a potent prognostic factor in Stage III colorectal cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Lymph Nodes / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dis Colon Rectum. 2007 Sep;50(9):1484; author reply 1484-5 [17661142.001]
  • (PMID = 17080279.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, Mayer RJ: Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol; 2005 Dec 1;23(34):8671-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
  • PURPOSE: In 1990, fluorouracil (FU) plus levamisole for 1 year became standard adjuvant treatment for patients with high-risk stages II and III colon cancer.
  • INT-0089 has long-term follow-up of the largest clinical trial of patients with high-risk colon cancer, documenting not only the durability of the treatment effects, but also the natural history of patients with high-risk colon cancer, and analyses of treatment based on age, race, and comorbid conditions such as obesity, diabetes, and second primary cancers.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314627.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA15488; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA66636
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 12001-76-2 / Vitamin B Complex; 2880D3468G / Levamisole; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


42. Chin CC, Wang JY, Yeh CY, Kuo YH, Huang WS, Yeh CH: Metastatic lymph node ratio is a more precise predictor of prognosis than number of lymph node metastases in stage III colon cancer. Int J Colorectal Dis; 2009 Nov;24(11):1297-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic lymph node ratio is a more precise predictor of prognosis than number of lymph node metastases in stage III colon cancer.
  • OBJECTIVE: The objective of this study is to assess the value of metastatic lymph node ratio (LNR) in predicting disease-free survival (DFS) in patients with stage III adenocarcinoma of the colon.
  • MATERIALS AND METHODS: From 1995 to 2003 inclusively, a total of 624 patients featuring stage III adenocarcinoma of the colon underwent curative resection.
  • In T3/4LNR1 patients (n = 411), there was no difference in survival between those with N1 stage and those with N2 stage.
  • Cox proportional hazards regression analysis revealed that N stage (number of positive lymph nodes) was not a significant factor when LNR was taken into consideration.
  • CONCLUSIONS: LNR is a more precise predictor of 5-year DFS than number of positive lymph nodes (N stage) in patients with stage III colon cancer.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2004 Jun;27(3):304-6 [15170153.001]
  • [Cites] J Gastrointest Surg. 2002 Nov-Dec;6(6):883-88; discussion 889-90 [12504228.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):27-34 [11829427.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(2):272-9 [15661553.001]
  • [Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):433-41 [17374833.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]
  • [Cites] Gut. 2006 Nov;55(11):1681 [17047131.001]
  • [Cites] Ann Surg Oncol. 2007 May;14(5):1712-7 [17253102.001]
  • [Cites] Eur J Surg Oncol. 2005 Feb;31(1):59-66 [15642427.001]
  • [Cites] Breast Cancer Res. 2004;6(6):R680-8 [15535850.001]
  • [Cites] Am J Surg. 2007 Dec;194(6):827-31; discussion 831-2 [18005779.001]
  • [Cites] Eur J Surg Oncol. 2008 Jul;34(7):771-5 [18079086.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8706-12 [16314630.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71 [12513963.001]
  • [Cites] Ann Surg Oncol. 2008 Jun;15(6):1600-8 [18327530.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):458-63 [11923600.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):179-89 [11812939.001]
  • [Cites] Am Surg. 2004 Mar;70(3):235-40; discussion 240 [15055847.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]
  • [Cites] Cancer. 1967 Nov;20(11):1976-85 [6061631.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):219-25 [15687365.001]
  • (PMID = 19479270.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


43. West NP, Morris EJ, Rotimi O, Cairns A, Finan PJ, Quirke P: Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study. Lancet Oncol; 2008 Sep;9(9):857-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study.
  • We aimed to assess the quality of colon cancer surgery by studying the extent of variation in the plane of surgical resection, the amount of tissue removed, and its association with survival.
  • METHODS: All resections for primary colon adenocarcinoma done at Leeds General Infirmary (Leeds, UK) between Jan 1, 1997, and June 30, 2002, were identified.
  • However, this association was no longer significant in the multivariate model (HR 0.86 [95% CI 0.56-1.31], p=0.472), but was especially noted in patients with stage III cancers (HR 0.45 [95% CI 0.24-0.85], p=0.014; multivariate analysis).
  • INTERPRETATION: As previously shown in the rectum, we have now shown there is marked variability in the plane of surgery achieved in colon cancer.
  • Improving the plane of dissection might improve survival, especially in patients with stage III disease.
  • If confirmed by clinical trial data, such as from the ongoing National Cancer Research Institute Fluoropyrimidine, Oxaliplatin and Targeted Receptor pre-Operative Therapy for colon cancer (FOxTROT) trial of neoadjuvant chemotherapy in advanced resectable colon cancer, improvement of the plane of dissection might be a new cost-effective method of decreasing morbidity and mortality in patients with colon cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / standards. Colonic Neoplasms / surgery. Neoplasm Recurrence, Local / prevention & control. Quality of Health Care

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2008 Sep;9(9):815-7 [18760238.001]
  • (PMID = 18667357.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 9805; United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


44. Liang Z, Hu WD, Gu ZD, Xiong HC, Chen KN: [Evaluation of transhiatus esophagectomy for patients with esophageal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Sep;11(5):451-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: These 46 patients included 44 esophageal squamous cell carcinomas,1 esophageal adenocarcinoma and 1 esophageal carcinoid.
  • All the patients were classified according to UICC TNM stage classification: 3 cases as stage 0, 6 cases as stage I, 17 cases as stage II a, 2 cases as stage II b, 16 cases as stage III.
  • Reconstruction with stomach was performed in 42 cases and with colon interposition in 4 cases.All the tumors were resected, and there was no perioperative death.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803048.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


45. Phelip JM, Molinié F, Delafosse P, Launoy G, Trétarre B, Bara S, Buémi A, Velten M, Danzon A, Ganry O, Bouvier AM, Grosclaude P, Faivre J: A population-based study of adjuvant chemotherapy for stage-II and -III colon cancers. Gastroenterol Clin Biol; 2010 Feb;34(2):144-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A population-based study of adjuvant chemotherapy for stage-II and -III colon cancers.
  • BACKGROUND: Although clinical trials have demonstrated that adjuvant chemotherapy improves survival for stage-III colon cancer, the benefits remain controversial for stage-II lesions.
  • The objective of the present study was to determine the extent to which adjuvant chemotherapy is used for patients with stage-II and -III colon cancers.
  • METHODS: The study population comprised 1074 patients with stage-II and -III colon cancers diagnosed in 2000 in 12 French administrative districts and recorded in population-based cancer registries.
  • RESULTS: Overall, 20.4% of patients with stage II and 61.9% with stage III received adjuvant chemotherapy.
  • Among stage-II patients, those receiving chemotherapy decreased from 57.6% in patients aged <or=50 years to 1.1% in those aged >or=85.
  • The corresponding percentages with stage III were 93.6% and 1.4%.
  • In multivariate analyses, other factors found to be independently and significantly associated with administration of adjuvant chemotherapy for stage II were extension of the cancer (stage IIA vs. stage IIB), clinical presentation (obstruction or perforation vs. uncomplicated cancer) and discussion of the case at a multidisciplinary case-review meeting.
  • For stage III, apart from age, discussion of the case at a multidisciplinary meeting was the only factor independently associated with administration of chemotherapy.
  • CONCLUSION: Adjuvant chemotherapy for stage-III colon cancer is used extensively for patients under 75 years of age.
  • On the other hand, a substantial percentage of stage-II colon cancer patients receive adjuvant chemotherapy despite its uncertain benefits.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20079591.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


46. Puppa G, Maisonneuve P, Sonzogni A, Masullo M, Chiappa A, Valerio M, Zampino MG, Franceschetti I, Capelli P, Chilosi M, Menestrina F, Viale G, Pelosi G: Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma. Br J Cancer; 2007 Apr 10;96(7):1118-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma.
  • In this study, we investigated the expression of fascin in 228 advanced colonic adenocarcinoma patients with a long follow-up.
  • Fascin correlated significantly with sex, tumour grade and stage, mucinous differentiation, number of metastatic lymph nodes, extranodal tumour extension, and the occurrence of distant metastases.
  • [MeSH-major] Adenocarcinoma / metabolism. Carrier Proteins / metabolism. Colonic Neoplasms / metabolism. Microfilament Proteins / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1993 Feb 15;71(4):1368-83 [8435813.001]
  • [Cites] J Cutan Pathol. 2002 Aug;29(7):430-8 [12139639.001]
  • [Cites] Am J Pathol. 1996 Feb;148(2):593-600 [8579121.001]
  • [Cites] In Vivo. 1996 Mar-Apr;10(2):153-60 [8744794.001]
  • [Cites] J Cell Biol. 1996 Sep;134(5):1271-81 [8794867.001]
  • [Cites] Hum Pathol. 1996 Nov;27(11):1124-34 [8912819.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):15-24 [9102255.001]
  • [Cites] Mol Biol Cell. 1997 Nov;8(11):2345-63 [9362073.001]
  • [Cites] Mol Biol Cell. 1998 May;9(5):993-1006 [9571235.001]
  • [Cites] J Cell Biol. 1998 Oct 5;143(1):121-33 [9763425.001]
  • [Cites] J Biol Chem. 1999 Feb 26;274(9):5443-53 [10026156.001]
  • [Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308 [15537574.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):69-80 [12507891.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):241-50 [12525515.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):537-47 [12592367.001]
  • [Cites] Eur J Cancer. 2003 Apr;39(6):718-27 [12651195.001]
  • [Cites] Lung Cancer. 2003 Nov;42(2):203-13 [14568688.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1572-82 [15117979.001]
  • [Cites] Histopathology. 1986 May;10(5):437-59 [3721406.001]
  • [Cites] J Cell Biol. 1986 Aug;103(2):631-40 [3525578.001]
  • [Cites] Cell Struct Funct. 1988 Oct;13(5):373-85 [3224379.001]
  • [Cites] Oncology. 2004;67(3-4):262-70 [15557788.001]
  • [Cites] Surg Oncol. 2004 Aug-Nov;13(2-3):93-101 [15572091.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):186-92 [15671545.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2597-605 [15814639.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Sep;37(9):1787-804 [16002322.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):741-6 [16084942.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):355-62 [16185662.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 8):11-4 [16360006.001]
  • [Cites] Clin Colorectal Cancer. 2006 May;6(1):38-45 [16796790.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Sep;30(3):538-42 [16870459.001]
  • [Cites] J Clin Pathol. 2006 Sep;59(9):958-64 [16524962.001]
  • [Cites] BMC Cancer. 2006;6:241 [17029629.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1362-6 [14571738.001]
  • [Cites] J Histochem Cytochem. 2000 Feb;48(2):163-6 [10639482.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):870-3 [10970687.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):83-8 [11206843.001]
  • [Cites] J Cell Biol. 2001 Mar 19;152(6):1169-82 [11257118.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2754-9 [11753948.001]
  • [Cites] Bioessays. 2002 Apr;24(4):350-61 [11948621.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):52-9 [12109856.001]
  • [Cites] DNA Cell Biol. 1994 Aug;13(8):821-7 [8068206.001]
  • (PMID = 17375048.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin
  • [Other-IDs] NLM/ PMC2360113
  •  go-up   go-down


47. Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, Chen WT, Cheng JD: Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res; 2007 Mar 15;13(6):1736-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical implications of fibroblast activation protein in patients with colon cancer.
  • PURPOSE: Human fibroblast activation protein (FAP)/seprase is a 97-kDa surface glycoprotein expressed on tumor associated fibroblasts in the majority of epithelial cancers including colon adenocarcinomas.
  • The primary objective of this study was to evaluate the clinical significance of stromal FAP in human colon cancers by immunohistochemisty.
  • EXPERIMENTAL DESIGN: Sections of paraffin-embedded resected primary human colon cancer specimens from 1996 through 2001 within the Fox Chase Cancer Center tumor bank were stained with D8 antibody directed against FAP/seprase.
  • RESULTS: One hundred thirty-eight patients with resected specimens were available for study (mean follow-up, 1,050 days) with 6 (4%) stage I, 52 (38%) stage II, 43 (31%) stage III, and 37 (27%) stage IV patients.
  • Stromal FAP was found to correlate inversely with tumor stage (semiquantitative, P = 0.01; intensity, P = 0.009) and with tumor size of the tumor xenograft model (correlation coefficient, -0.61; P = 0.047), suggesting that stromal FAP may have a greater role in the early development of tumors.
  • CONCLUSION: Our data indicate that patients whose colon tumors have high levels of stromal FAP are more likely to have aggressive disease progression and potential development of metastases or recurrence.
  • It also suggests that the effects of FAP inhibition should be investigated in earlier-stage tumors, given its high levels and potential effect earlier in the course of the disease.
  • [MeSH-major] Adenocarcinoma / genetics. Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Colonic Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Serine Endopeptidases / genetics

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17363526.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA006927; United States / NCI NIH HHS / CA / CA09035; United States / NCI NIH HHS / CA / CA090468; United States / NCI NIH HHS / CA / CA103991; United States / PHS HHS / / W81XWH-04-1-0709
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Membrane Proteins; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases
  •  go-up   go-down


48. Chew MH, Yeo SA, Ng ZP, Lim KH, Koh PK, Ng KH, Eu KW: Critical analysis of mucin and signet ring cell as prognostic factors in an Asian population of 2,764 sporadic colorectal cancers. Int J Colorectal Dis; 2010 Oct;25(10):1221-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SRC and MA are more likely to have locally advanced lesions (T3/T4; SRC 100%, MA 90%, OA 83%, p = 0.002) and lymph node metastases (SRC 89%, MA 61%, OA 52%, p < 0.0001) and present with an advanced stage at diagnosis (stage III/IV SRC 94%, MA 67%, OA 56%, p < 0.0001).
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Colorectal Neoplasms / diagnosis. Mucins / analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 2000 Oct;75(2):103-7 [11064389.001]
  • [Cites] Int J Oncol. 2009 Apr;34(4):1109-15 [19287969.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1161-8 [15868237.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):50-5 [18030531.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5660-5 [14654549.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1453-6 [10348829.001]
  • [Cites] Dis Colon Rectum. 2004 Jan;47(1):78-85 [14719155.001]
  • [Cites] Int J Colorectal Dis. 2004 Mar;19(2):102-7 [14752674.001]
  • [Cites] Hepatogastroenterology. 2006 Nov-Dec;53(72):845-9 [17153438.001]
  • [Cites] J Surg Oncol. 2001 Aug;77(4):282-3 [11473380.001]
  • [Cites] Gastroenterol Hepatol. 2002 Nov;25(9):534-40 [12435303.001]
  • [Cites] Oncology. 1994 Jan-Feb;51(1):30-4 [8265100.001]
  • [Cites] Dis Colon Rectum. 2006 Sep;49(9):1275-83 [16912910.001]
  • [Cites] Dis Colon Rectum. 1999 Sep;42(9):1176-80 [10496558.001]
  • [Cites] Am J Surg. 2007 Sep;194(3):294-8 [17693269.001]
  • [Cites] AMA Arch Surg. 1951 Jan;62(1):79-91 [14789350.001]
  • [Cites] J Surg Oncol. 2000 Feb;73(2):70-4 [10694641.001]
  • [Cites] Chin Med J (Engl). 2009 Jul 5;122(13):1486-91 [19719934.001]
  • [Cites] Cancer Lett. 1996 Jun 5;103(2):163-70 [8635153.001]
  • [Cites] Dis Colon Rectum. 1993 Jan;36(1):49-54 [8380140.001]
  • [Cites] J Pathol. 2007 Jul;212(3):278-86 [17471475.001]
  • [Cites] Tech Coloproctol. 2004 Nov;8 Suppl 1:s123-5 [15655594.001]
  • [Cites] Med Arh. 2007;61(1):26-9 [17582971.001]
  • [Cites] J Gastroenterol Hepatol. 1996 Jan;11(1):77-81 [8672747.001]
  • [Cites] Dis Colon Rectum. 1999 Dec;42(12):1618-25 [10613484.001]
  • [Cites] Dis Colon Rectum. 2003 Feb;46(2):160-7 [12576888.001]
  • [Cites] ANZ J Surg. 2001 Dec;71(12):703-6 [11906382.001]
  • (PMID = 20686777.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


49. Liebig C, Ayala G, Wilks J, Verstovsek G, Liu H, Agarwal N, Berger DH, Albo D: Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol; 2009 Nov 1;27(31):5131-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a subset analysis comparing patients with node-negative disease with patients with stage III disease, the 5-year disease-free survival rate was 56% for stage III patients versus 29% for patients with node-negative, PNI-positive tumors (P = .0002).
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology. Peripheral Nerves / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1986 Oct;96(10):1145-8 [3762289.001]
  • [Cites] Head Neck Surg. 1986 Jul-Aug;8(6):401-8 [3721882.001]
  • [Cites] Dis Colon Rectum. 1991 Sep;34(9):798-804 [1914747.001]
  • [Cites] Br J Cancer. 1992 Jan;65(1):102-7 [1733432.001]
  • [Cites] Am J Surg Pathol. 1993 Apr;17(4):336-41 [8494103.001]
  • [Cites] Br J Surg. 1996 Jan;83(1):46-50 [8653361.001]
  • [Cites] Pancreas. 1996 May;12(4):357-61 [8740402.001]
  • [Cites] Cancer. 1996 Sep 15;78(6):1267-71 [8826950.001]
  • [Cites] Dis Colon Rectum. 1997 Mar;40(3):326-31 [9118749.001]
  • [Cites] J Surg Oncol. 1997 Jul;65(3):164-70 [9236924.001]
  • [Cites] Mol Cell Endocrinol. 1997 Oct 31;134(1):15-22 [9406845.001]
  • [Cites] Oncol Rep. 1998 Jan-Feb;5(1):73-6 [9458297.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Jun;124(6):637-40 [9639472.001]
  • [Cites] Am J Surg. 1999 May;177(5):392-5 [10365877.001]
  • [Cites] Clin Exp Metastasis. 2004;21(4):285-92 [15554384.001]
  • [Cites] Arch Pathol Lab Med. 2005 Mar;129(3):354-9 [15737030.001]
  • [Cites] Cell Death Differ. 2005 Aug;12(8):1044-56 [16015381.001]
  • [Cites] Cancer. 2007 Jan 1;109(1):13-24 [17123267.001]
  • [Cites] Am J Clin Oncol. 2007 Feb;30(1):93-6 [17278901.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Dis Colon Rectum. 2008 May;51(5):503-7 [18322753.001]
  • [Cites] Colorectal Dis. 2008 Nov;10(9):879-86 [19037929.001]
  • [Cites] Acta Chir Iugosl. 2008;55(3):39-44 [19069691.001]
  • [Cites] Cancer. 2009 Aug 1;115(15):3379-91 [19484787.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2005 May;(216):34-63 [16019758.001]
  • [Cites] Cancer. 1988 Mar 1;61(5):1018-23 [3338045.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1985 Jul-Aug;94(4 Pt 1):426-7 [4026129.001]
  • [Cites] Dig Dis. 1999;17(2):67-79 [10545712.001]
  • [Cites] Urology. 1999 Dec;54(6):1039-43 [10604705.001]
  • [Cites] J Urol. 2001 Jan;165(1):114-8 [11125378.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 May;280(5):G958-67 [11292605.001]
  • [Cites] Eur Urol. 2001 Sep;40(3):308-12 [11684847.001]
  • [Cites] Dis Colon Rectum. 2001 Nov;44(11):1682-8 [11711742.001]
  • [Cites] Prostate. 2001 Nov 1;49(3):213-23 [11746267.001]
  • [Cites] Digestion. 2002;66(2):79-88 [12428066.001]
  • [Cites] Urology. 2003 Apr;61(4):870-5 [12670591.001]
  • [Cites] Pancreas. 2003 May;26(4):322-5 [12717262.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):19-24 [14697416.001]
  • [Cites] Jpn J Clin Oncol. 2004 Jun;34(6):323-8 [15333684.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6082-90 [15342391.001]
  • [Cites] Anat Rec A Discov Mol Cell Evol Biol. 2004 Sep;280(1):821-6 [15382019.001]
  • [CommentIn] Z Gastroenterol. 2010 Dec;48(12):1405-6 [21125515.001]
  • [CommentIn] J Clin Oncol. 2010 Jul 20;28(21):e358-60; author reply e361-2 [20385977.001]
  • (PMID = 19738119.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2773472
  •  go-up   go-down


50. Viehl CT, Ochsner A, von Holzen U, Cecini R, Langer I, Guller U, Laffer U, Oertli D, Zuber M: Inadequate quality of surveillance after curative surgery for colon cancer. Ann Surg Oncol; 2010 Oct;17(10):2663-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inadequate quality of surveillance after curative surgery for colon cancer.
  • BACKGROUND: Colon cancer patients are at risk for recurrence.
  • The objective of this study is to analyze the quality of surveillance after curative surgery for colon cancer among a cohort of Swiss patients.
  • PATIENTS AND METHODS: After curative surgery, 129 stage I-III colon cancer patients were followed by chart review, questionnaires, and phone interviews.
  • CONCLUSIONS: The quality of surveillance after curative surgery for colon cancer among a cohort of Swiss patients is inadequate.
  • [MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Continuity of Patient Care

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20429036.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


51. Hohenberger W, Merkel S, Weber K: [Lymphadenectomy with tumors of the lower gastrointestinal tract]. Chirurg; 2007 Mar;78(3):217-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Lymphadenektomie bei Tumoren des unteren Gastrointestinaltraktes.
  • Following these rules and with no adjuvant systemic treatment, 5-year survival figures of 80% can be reached, even for UICC stage III disease.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Anus Neoplasms / pathology. Anus Neoplasms / surgery. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / surgery. Humans. Intestines / pathology. Intestines / surgery. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Lymphoma / pathology. Lymphoma / surgery. Neoplasm Staging. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / surgery. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Jpn J Surg. 1983 Nov;13(6):557-73 [6672390.001]
  • [Cites] Fortschr Med. 1986 Feb 27;104(8):167-70 [3957212.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] Chirurg. 2003 Oct;74(10):897-904 [14605731.001]
  • [Cites] World J Surg. 2006 Mar;30(3):391-8; discussion 399 [16479330.001]
  • [Cites] Cancer Causes Control. 2005 Sep;16(7):781-7 [16132788.001]
  • [Cites] Langenbecks Arch Surg. 1998 Dec;383(6):402-8 [9921939.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Gut. 2005 Jun;54 Suppl 4:iv1-16 [15888809.001]
  • [Cites] Br J Surg. 2003 Dec;90(12):1580-5 [14648739.001]
  • [Cites] J Am Coll Surg. 1997 Jun;184(6):584-8 [9179114.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2912-9 [12885809.001]
  • [Cites] World J Surg. 1996 Feb;20(2):132-41 [8661808.001]
  • [Cites] Chirurg. 2004 Aug;75(8):761-6 [15232693.001]
  • [Cites] Am J Surg. 1997 Mar;173(3):237-9 [9124635.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] Am J Surg. 2006 Mar;191(3):305-10 [16490536.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):77-84 [11443612.001]
  • [Cites] Z Gastroenterol. 2004 Sep;42(9):1067-72 [15455287.001]
  • [Cites] Surgery. 1998 Oct;124(4):612-7; discussion 617-8 [9780979.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):162-8 [15654796.001]
  • [Cites] Chirurg. 2007 Aug;78(8):739-47 [17569018.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] J R Soc Med. 1988 Sep;81(9):503-8 [3184105.001]
  • [Cites] Surg Endosc. 1989;3(2):96-9 [2672395.001]
  • [Cites] J Am Coll Surg. 1997 May;184(5):475-80 [9145067.001]
  • [Cites] Digestion. 1994;55 Suppl 3:11-23 [7698533.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1496-502 [12432298.001]
  • [Cites] Scand J Surg. 2003;92(1):45-52 [12705550.001]
  • [Cites] Chirurg. 2006 Jan;77(1):33-40 [16372188.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2740-6 [12860953.001]
  • (PMID = 17333036.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


52. Thirunavukarasu P, Sathaiah M, Singla S, Sukumar S, Karunamurthy A, Pragatheeshwar KD, Lee KK, Zeh H 3rd, Kane KM, Bartlett DL: Medullary carcinoma of the large intestine: a population based analysis. Int J Oncol; 2010 Oct;37(4):901-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Medullary carcinoma (MC) of the colorectum is a relatively new histological type of adenocarcinoma characterized by poor glandular differentiation and intraepithelial lymphocytic infiltrate.
  • We observed that MCs were rare tumors, constituting approximately 5-8 cases for every 10,000 colon cancers diagnosed, with a mean annual incidence of 3.47 (+/-0.75) per 10 million population.
  • MCs were twice as common in females, who presented at a later age, with a lower stage and a trend towards favorable prognosis.
  • MCs were most common in the proximal colon (74%), where they present at a later age than the sigmoid colon.
  • MCs commonly presented with Stage II disease, with 10% presenting with metastases.
  • Although MCs showed a trend towards better early overall survival, undifferentiated MCs present more commonly with Stage III, with comparatively worse early outcomes.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Medullary / epidemiology. Colorectal Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2429-38 [10561306.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):527-35 [11159189.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2239-48 [11733373.001]
  • [Cites] Histopathology. 1977 Jan;1(1):77-84 [615835.001]
  • [Cites] Am J Pathol. 1994 Jul;145(1):148-56 [8030745.001]
  • [Cites] J Clin Oncol. 2010 Jan 10;28(2):264-71 [19949014.001]
  • [Cites] Hum Pathol. 1999 Jul;30(7):843-8 [10414504.001]
  • [Cites] Am J Clin Pathol. 2005 Jan;123(1):56-65 [15762280.001]
  • [Cites] Hum Pathol. 2009 Mar;40(3):398-404 [18992917.001]
  • [Cites] Oncology (Williston Park). 2009 Mar;23(3):288-95 [19418830.001]
  • [Cites] Am J Pathol. 1997 May;150(5):1815-25 [9137104.001]
  • (PMID = 20811712.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA113263
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  • [Other-IDs] NLM/ NIHMS609288; NLM/ PMC4127912
  •  go-up   go-down


53. Arkenau HT, Rettig K, Porschen R: Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion. Int J Colorectal Dis; 2005 May;20(3):258-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion.
  • BACKGROUND: Adjuvant postoperative treatment with 5-fluorouracil (5-FU) and leucovorin in curatively resected stage III colon cancer significantly reduces the risk of cancer recurrence and improves survival.
  • PATIENTS AND METHODS: Patients with a curatively resected UICC stage III colon cancer were stratified according to T, N and G category and randomly assigned to receive one of the three adjuvant treatment schemes: 5-FU 450 mg/m2 and leucovorin 100 mg/m2 x 5 days every 4 weeks; six cycles, arm A; 24-h infusion of high-dose 5-FU/leucovorin 2,600 mg/m2 and 500 mg/m2, two cycles of six applications, arm B; 24-h infusion of high-dose 5-FU 2,600 mg/m2, two cycles of six applications, arm C.
  • CONCLUSION: There is no statistical difference in efficacy and toxicity in patients receiving either high-dose 5-FU with or without leucovorin or the standard 5-FU bolus regime after a curative resection of a stage III colon cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Colectomy / methods. Colonic Neoplasms / drug therapy. Fluorouracil / administration & dosage. Leucovorin / administration & dosage

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Minerva Chir. 2003 Aug;58(4):491-502, 502-7 [14603161.001]
  • [Cites] Ann Oncol. 2003 Mar;14(3):395-9 [12598344.001]
  • [Cites] Ann Oncol. 1996 Jan;7(1):42-6 [9081390.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1787-94 [11251010.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1735-43 [14630678.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3277-83 [15249584.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2896-903 [12885807.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1303-11 [7751875.001]
  • [Cites] Int J Cancer. 1999 Sep 24;83(1):18-29 [10449602.001]
  • [Cites] Int J Cancer. 1995 Sep 27;63(1):43-8 [7558450.001]
  • [Cites] J Clin Oncol. 1991 Apr;9(4):625-30 [2066758.001]
  • [Cites] Chirurg. 1994 Apr;65(4):287-97 [8020349.001]
  • (PMID = 15549327.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


54. Georgescu SO, Neacşu CN, Vintilă D, Popa P, Forţu L, Nistor A, Ferariu D, Târcoveanu E: [Long-term results after surgery for colorectal adenocarcinoma, stage I-III. Problems of prognosis]. Rev Med Chir Soc Med Nat Iasi; 2007 Oct-Dec;111(4):932-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results after surgery for colorectal adenocarcinoma, stage I-III. Problems of prognosis].
  • [Transliterated title] Rezultate la distanţă după tratamentul chirurgical al adenocarcinomului colo-rectal stadiile I-III. Probleme de prognostic.
  • STUDY DESIGN: Prospective study on 142 consecutively cases with stage I to III colorectal adenocarcinomas (TNM AJCC/UICC) in which patients underwent potentially curative surgery in one single public health service (1st Surgical Clinic Iaşi, Romania) between 2004 and 2005.
  • The surgical procedures performed were the following: right colectomy (n = 54; 30%); transverse colectomy (n = 2; 1.4%); left colectomy (n = 19; 13.4%); segmental colon resection with anastomosis (n = 5 ; 3.5%); Hartmann procedure (n = 18; 12.7%); anterior rectal resection (n = 11; 7.7%) and abdominoperineal resection (n = 33; 23.2%).
  • RESULTS: The factors with a significant negative influence in overall survival and 42-months survival rates were: the age over 70 years, the emergency surgery related to cancer's complications, the advanced AJCC/ UICC stage, vascular invasion, perineural invasion, the recurrence of disease, the moderate and lower differentiated adenocarcinoma and incomplete or not performed chemotherapy.
  • CONCLUSION: Even with a radical surgical approach the advanced stage of colorectal adenocarcinoma has a low prognostic, but some other factors have also a high significance in postoperative outcome.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Colectomy / methods. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18389783.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


55. Kornmann M, Formentini A, Ette C, Henne-Bruns D, Kron M, Sander S, Baumann W, Kreuser ED, Staib L, Link KH: Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment. Eur J Surg Oncol; 2008 Dec;34(12):1316-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment.
  • AIM: Adjuvant chemotherapy is recommended for stage III colon cancer.
  • The aim of this study was to identify important prognostic factors among patients with colon cancer receiving adjuvant 5-FU-based treatment.
  • METHODS: Data sets of 855 colon cancer patients treated between 1992 and 1999 within a multicenter adjuvant trial comparing 5-FU modulation with folinic acid or interfereron-alpha were examined.
  • In the future, this may result in adjuvant treatment of stage III colon cancer adjusted for the risk of substages.
  • [MeSH-major] Adenocarcinoma / mortality. Antimetabolites, Antineoplastic / therapeutic use. Colonic Neoplasms / mortality. Fluorouracil / therapeutic use

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313881.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Immunologic Factors; 0 / Interferon-alpha; 12001-76-2 / Vitamin B Complex; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


56. Liang JT, Lai HS, Lee PH, Chang KJ: Laparoscopic pelvic autonomic nerve-preserving surgery for sigmoid colon cancer. Ann Surg Oncol; 2008 Jun;15(6):1609-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic pelvic autonomic nerve-preserving surgery for sigmoid colon cancer.
  • BACKGROUND: To test the feasibility of laparoscopic approach in performing the simultaneous pelvic autonomic nerve preservation during standard anterior resection of sigmoid colon cancer.
  • RESULTS: A total of 112 patients (tumor, node, metastasis system stage I, n = 8; stage II, n = 54; stage III, n = 50; male, n = 58; female, n = 54; age [mean +/- standard deviation], 55.8 +/- 6.4 years) with good baseline genitourinary function were operated on with the intent of total preservation of pelvic autonomic nerves and curative resection of sigmoid colon cancer.
  • CONCLUSIONS: Under laparoscopy, we can clearly identify and preserve the pelvic autonomic nerves to retain genitourinary function in most patients undergoing oncologic resection of sigmoid colon cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Autonomic Pathways / surgery. Colectomy. Sigmoid Neoplasms / surgery. Trauma, Nervous System / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2004 Apr;91(4):465-8 [15048749.001]
  • [Cites] Tech Coloproctol. 2003 Apr;7(1):29-33 [12750952.001]
  • [Cites] Dis Colon Rectum. 2005 Dec;48(12):2354-61 [16408331.001]
  • [Cites] Br J Surg. 2005 Nov;92(11):1444-8 [16184622.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1124-32 [15997446.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):212-23 [16041212.001]
  • [Cites] World J Surg. 2003 Feb;27(2):190-6 [12616435.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1178-85 [12352233.001]
  • [Cites] J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208 [10782451.001]
  • [Cites] Semin Surg Oncol. 2000 Apr-May;18(3):235-43 [10757889.001]
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1354-7 [15362751.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):2206-14 [9951896.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14(4):1285-7 [17235719.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):109-17 [17066227.001]
  • [Cites] Int J Clin Oncol. 2006 Oct;11(5):339-43 [17058130.001]
  • [Cites] Dis Colon Rectum. 2004 Sep;47(9):1442-7 [15486739.001]
  • [Cites] Ann Surg. 1988 Oct;208(4):391-400 [3178328.001]
  • [Cites] Dis Colon Rectum. 1995 Nov;38(11):1162-8 [7587758.001]
  • [Cites] Cancer. 1996 Nov 1;78(9):1871-80 [8909305.001]
  • [Cites] Br J Surg. 1997 Apr;84(4):586-7 [9112939.001]
  • [Cites] Urology. 1997 Jun;49(6):822-30 [9187685.001]
  • [Cites] Br J Surg. 1998 Aug;85(8):1162 [9718031.001]
  • (PMID = 18365285.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2373867
  •  go-up   go-down


57. Morris M, Platell C, Iacopetta B: Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res; 2008 Mar 1;14(5):1413-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy.
  • The aim of the present study was to investigate the prognostic significance of TILs and other routinely reported pathologic features in colon cancer, particularly in relation to the use of adjuvant chemotherapy.
  • EXPERIMENTAL DESIGN: Pathologic markers, disease-specific survival, and the use of adjuvant chemotherapy were recorded in a retrospective, population-based series of 1,156 stage III colon cancer patients with a median follow-up time of 52 months.
  • RESULTS: In patients treated by surgery alone (n = 851), markers with significant prognostic value included poor histologic grade, T4 stage, N2 nodal status, vascular invasion, and perforation, but not the presence of TILs.
  • Because the presence of TILs reflects an adaptive immune response and perforation is associated with inflammatory response, these results suggest that there may be interactions between the immune system and chemotherapy leading to improved survival of colon cancer patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Colonic Neoplasms / drug therapy. Fluorouracil / therapeutic use. Intestinal Perforation / diagnosis. Lymphocytes, Tumor-Infiltrating / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18316563.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


58. Looi LM, Ng MH, Cheah PL: Telomerase activation in neoplastic cell immortalization and tumour progression. Malays J Pathol; 2007 Jun;29(1):33-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is in contrast to normal somatic cells which are subject to a "mitotic clock," a phenomenon that has been linked to telomeric shortening after each round of cell replication, so that eventually the loss of genetic material reaches a critical stage and the cells undergo senescence and cell death.
  • Specimens comprised 33 breast lesions (10 infiltrating breast adenocarcinoma, 13 fibroadenoma and 10 non-neoplastic breast tissue), 27 colonic lesions (17 colonic adenocarcinoma and 10 non-neoplastic colonic mucosa) and 42 cervical lesions (20 cervical carcinoma and 22 non-neoplastic cervical tissues).
  • Telomerase activity was found in 6 (60%) of 10 breast carcinomas, 6 (46%) of 13 fibroadenomas, none of the 10 nonneoplastic breast samples, 3 (17.6%) of 17 colon carcinomas and none of the 10 non-neoplastic colonic mucosal samples, 12 (60%) of 20 cervical carcinoma and 3 (13.6%) of 22 non-neoplastic cervical samples.
  • 5/10 (50%) Stage I, 4/7 (57%) Stage II, 2/2 (100%) Stage III and 1/1 (100%) Stage IV cervical carcinomas showed telomerase activity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19105326.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Malaysia
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


59. Seo T, Tatsuguchi A, Shinji S, Yonezawa M, Mitsui K, Tanaka S, Fujimori S, Gudis K, Fukuda Y, Sakamoto C: Microsomal prostaglandin E synthase protein levels correlate with prognosis in colorectal cancer patients. Virchows Arch; 2009 Jun;454(6):667-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The localization of each PGES and COX-2 protein was examined by immunohistochemistry in 155 surgical resections and correlated to clinicopathological factors and patient prognosis. mPGES-1 mRNA and protein levels were significantly higher in CRC than in paired normal tissues. mPGES-1 immunoreactivity localized in cancer cells in 43% of cases. mPGES-2 immunoreactivity was significantly more pronounced in cancer cells than in adjacent normal epithelium in 36% of cases. cPGES immunoreactivity was homogeneous in cancer cells and thus determined constitutive. mPGES-1 and mPGES-2 correlated with significantly worse prognosis in stage I-III patients.
  • [MeSH-major] Adenocarcinoma / enzymology. Colorectal Neoplasms / enzymology. Intramolecular Oxidoreductases / metabolism. Microsomes / enzymology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1092-102 [15713943.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):16355-64 [11847219.001]
  • [Cites] Mol Carcinog. 2006 Jun;45(6):447-54 [16688727.001]
  • [Cites] J Biochem Mol Biol. 2005 Nov 30;38(6):633-8 [16336776.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):409-12 [9458081.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Mar 8;291(4):884-9 [11866447.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37937-47 [12835322.001]
  • [Cites] J Immunol. 2001 Jul 1;167(1):469-74 [11418684.001]
  • [Cites] Gut. 2006 Jan;55(1):54-61 [16085694.001]
  • [Cites] Gut. 2006 Jan;55(1):115-22 [16118353.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):885-95 [16943401.001]
  • [Cites] N Engl J Med. 2007 May 24;356(21):2131-42 [17522398.001]
  • [Cites] J Biol Chem. 2000 Oct 20;275(42):32783-92 [10869354.001]
  • [Cites] Br J Pharmacol. 2004 Apr;141(7):1091-7 [15023855.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):130-40 [16491072.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7220-5 [10377395.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Jul 18;372(1):249-53 [18485889.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):63-75 [15000150.001]
  • [Cites] Hum Pathol. 2007 Dec;38(12 ):1826-35 [17868774.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4754-60 [16000571.001]
  • [Cites] J Biol Chem. 2000 Oct 20;275(42):32775-82 [10922363.001]
  • [Cites] Dis Colon Rectum. 2006 Aug;49(8):1184-92 [16752205.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jun 27;306(2):577-81 [12804604.001]
  • [Cites] Cell. 1998 May 29;93(5):705-16 [9630216.001]
  • [Cites] Lab Invest. 2005 Feb;85(2):225-36 [15531909.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):551-6 [14520691.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3251-9 [18451151.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):19396-405 [12626523.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):404-12 [12891542.001]
  • [Cites] J Pathol. 2006 Feb;208(3):356-63 [16353170.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12 ):3971-6 [11751489.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1391-9 [16614756.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):30253-63 [12050152.001]
  • [Cites] Mol Cancer. 2006 Nov 16;5:62 [17107625.001]
  • [Cites] Hum Pathol. 2004 Apr;35(4):488-95 [15116331.001]
  • (PMID = 19412621.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; 0 / RNA, Messenger; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.3 / PTGES protein, human; EC 5.3.99.3 / PTGES2 protein, human; EC 5.3.99.3 / Prostaglandin-E Synthases
  •  go-up   go-down


60. Sprenger T, Rothe H, Homayounfar K, Beissbarth T, Ghadimi BM, Becker H, Liersch T: Preoperative chemoradiotherapy does not necessarily reduce lymph node retrieval in rectal cancer specimens--results from a prospective evaluation with extensive pathological work-up. J Gastrointest Surg; 2010 Jan;14(1):96-103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Specimens from 64 consecutive patients with stage II/III rectal cancer receiving preoperative 5-FU-based CRT were investigated.
  • [MeSH-major] Adenocarcinoma / surgery. Lymph Nodes / pathology. Neoadjuvant Therapy. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2008 Mar;51(3):277-83 [18183463.001]
  • [Cites] Cancer. 2009 Dec 1;115(23):5432-40 [19673001.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):157-63 [11134208.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1976-84 [11283130.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):780 [11531267.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):179-89 [11812939.001]
  • [Cites] Arch Surg. 2002 Feb;137(2):206-10 [11822961.001]
  • [Cites] World J Surg. 2002 Mar;26(3):384-9 [11865379.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1729-34 [11919228.001]
  • [Cites] Am Surg. 2002 May;68(5):482-7 [12013294.001]
  • [Cites] Pathologe. 2003 Feb;24(1):61-5 [12601479.001]
  • [Cites] Semin Surg Oncol. 2003;21(1):19-22 [12923912.001]
  • [Cites] Arch Med Res. 2003 Jul-Aug;34(4):281-6 [12957524.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] Colorectal Dis. 2004 Sep;6(5):356-61 [15335370.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Front Radiat Ther Oncol. 1994;28:37-45 [7982602.001]
  • [Cites] J Am Coll Surg. 1995 Oct;181(4):335-46 [7551328.001]
  • [Cites] Int J Colorectal Dis. 1997;12(1):19-23 [9112145.001]
  • [Cites] CA Cancer J Clin. 1998 Jan-Feb;48(1):6-29 [9449931.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):666-72 [9708929.001]
  • [Cites] Lancet. 1999 Jan 30;353(9150):391-9 [9950460.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(2):272-9 [15661553.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):426-31 [15667963.001]
  • [Cites] Surg Today. 2005;35(6):442-5 [15912290.001]
  • [Cites] Int J Colorectal Dis. 2005 Sep;20(5):434-9 [15759124.001]
  • [Cites] APMIS. 2006 Mar;114(3):201-10 [16643187.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4062-8 [16943523.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):110-7 [17194912.001]
  • [Cites] J Gastrointest Surg. 2007 May;11(5):660-5 [17468927.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2573-9 [17577036.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4339-40 [17906196.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4379-86 [17906203.001]
  • [Cites] Dis Colon Rectum. 2007 Oct;50(10):1526-34 [17828403.001]
  • [Cites] Lancet. 2007 Dec 15;370(9604):2020-9 [18083404.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):456-61 [18164860.001]
  • [Cites] Tech Coloproctol. 2008 Mar;12(1):39-43 [18512011.001]
  • [Cites] J Natl Cancer Inst. 2008 Sep 17;100(18):1310-7 [18780863.001]
  • [Cites] J Gastrointest Surg. 2009 Feb;13(2):269-74 [18850250.001]
  • [Cites] Ann Surg. 2009 Jun;249(6):965-72 [19474683.001]
  • [Cites] Dis Colon Rectum. 2009 Jul;52(7):1278-84 [19571705.001]
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2106-11 [18362367.001]
  • (PMID = 19830503.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


61. Wirtzfeld DA, Mikula L, Gryfe R, Ravani P, Dicks EL, Parfrey P, Gallinger S, Pollett WG: Concordance with clinical practice guidelines for adjuvant chemotherapy in patients with stage I-III colon cancer: experience in 2 Canadian provinces. Can J Surg; 2009 Apr;52(2):92-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concordance with clinical practice guidelines for adjuvant chemotherapy in patients with stage I-III colon cancer: experience in 2 Canadian provinces.
  • The American Society of Clinical Oncology and Cancer Care Ontario have recommended adjuvant chemotherapy for patients with high-risk stage II colon cancer.
  • We evaluated differences in concordance with guidelines in the treatment of patients with stage I-III colon cancer in the Canadian provinces of Newfoundland and Labrador and Ontario.
  • METHODS: We assessed clinical data and treatment from January 1999 to December 2000 for 130 patients from Newfoundland and Labrador and 315 patients from Ontario who had stage I-III colon cancer.
  • We evaluated factors affecting the use of chemotherapy in patients with stage II disease.
  • RESULTS: No patients received adjuvant therapy for stage I disease.
  • Forty-five of 52 patients (87%) in Newfoundland and Labrador and 108 of 115 patients (94%) in Ontario received adjuvant chemotherapy for stage III colon cancer.
  • Twenty of 55 patients (36%) in Newfoundland and Labrador and 44 of 116 patients (38%) in Ontario received adjuvant therapy for stage II disease.
  • There was a strong trend toward using chemotherapy in patients with stage II disease who were 50 years or younger, independent of high-risk status.
  • CONCLUSION: Concordance with CPGs for adjuvant chemotherapy in patients with stage II colon cancer was not optimal.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Age Factors. Aged. Humans. Middle Aged. Multivariate Analysis. Newfoundland and Labrador. Ontario. Patient Selection. Registries. Risk Assessment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1999 Oct 20;282(15):1458-65 [10535437.001]
  • [Cites] Am J Gastroenterol. 2006 Jun;101(6):1320-8 [16771956.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Chronic Dis Can. 2000;21(2):81-6 [11007659.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3395-407 [15199087.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Intern Med J. 2004 Aug;34(8):492-500 [15317548.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] CMAJ. 1993 Feb 15;148(4):507-12 [8431814.001]
  • [Cites] N Engl J Med. 1993 May 13;328(19):1365-71 [8474513.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1369-72 [7577053.001]
  • [Cites] Nat Med. 1995 Apr;1(4):348-52 [7585065.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] Med Care Res Rev. 2004 Dec;61(4):453-73 [15536209.001]
  • [Cites] Health Aff (Millwood). 2005 Jan-Feb;24(1):18-28 [15647212.001]
  • [Cites] Cancer. 2005 Apr 25;105(2):101-9 [15643601.001]
  • [Cites] Eval Health Prof. 2006 Mar;29(1):65-88 [16510880.001]
  • [Cites] Qual Health Care. 1999 Sep;8(3):177-83 [10847875.001]
  • (PMID = 19399202.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2663496
  •  go-up   go-down


62. Sézeur A, Châtelet FP, Cywiner Ch, de Labriolle-Vaylet C, Chastang C, Billotey C, Malafosse M, Gallot D, Betton P, Montravers F, Carvajal-Gonzalez S, Askienazy S, Talbot JN, Rain JD, Milhaud G, Saumon G, Barbet J, Gruaz-Guyon A: Pathology underrates colon cancer extranodal and nodal metastases; ex vivo radioimmunodetection helps staging. Clin Cancer Res; 2007 Sep 15;13(18 Pt 2):5592s-5597s
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology underrates colon cancer extranodal and nodal metastases; ex vivo radioimmunodetection helps staging.
  • The benefit of adjuvant chemotherapy for patients upstaged with radioimmunodection should also be assessed because adjuvant chemotherapy improves the 5-year survival of stage III patients.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Colonic Neoplasms / radionuclide imaging. Indium Radioisotopes. Radioimmunodetection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875794.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Carcinoembryonic Antigen; 0 / Haptens; 0 / Indium Radioisotopes; 0 / Oligopeptides
  •  go-up   go-down


63. Mizushima T, Nomura M, Fujii M, Akamatsu H, Mizuno H, Tominaga H, Hasegawa J, Nakajima K, Yasumasa K, Yoshikawa M, Nishida T: Primary colorectal signet-ring cell carcinoma: clinicopathological features and postoperative survival. Surg Today; 2010 Mar;40(3):234-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinicopathological data of those patients were compared with those of 5792 patients with non-signet-ring cell colorectal carcinoma (5417 with well or moderately differentiated adenocarcinoma and 375 with poorly differentiated adenocarcinoma or mucinous carcinoma).
  • The overall 5-year survival rate in primary signet-ring cell carcinoma was significantly lower at 24.1%, in comparison to 77.5% in well or moderately differentiated adenocarcinoma and 57.7% in poorly differentiated adenocarcinoma or mucinous carcinoma.
  • Likewise, the postoperative survival in Stage III was also significantly worse.
  • On the other hand, no significant difference was observed in Stage II or IV.
  • CONCLUSION: The most important feature of primary colorectal signet-ring cell carcinoma is the advanced stage at the time of diagnosis.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Carcinoma, Signet Ring Cell / mortality. Carcinoma, Signet Ring Cell / pathology. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1996 Oct;91(10):2195-9 [8855747.001]
  • [Cites] Ann Surg Oncol. 1996 Jul;3(4):344-8 [8790846.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):50-5 [18030531.001]
  • [Cites] Oncology. 2007;72(1-2):64-8 [18004078.001]
  • [Cites] Hepatogastroenterology. 2006 Nov-Dec;53(72):845-9 [17153438.001]
  • [Cites] Oncology. 1994 Jan-Feb;51(1):30-4 [8265100.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):229-37 [14657227.001]
  • [Cites] Cancer. 1985 Dec 1;56(11):2723-6 [2996745.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] Dis Colon Rectum. 1999 Sep;42(9):1176-80 [10496558.001]
  • [Cites] AMA Arch Surg. 1951 Jan;62(1):79-91 [14789350.001]
  • [Cites] Surg Today. 2009;39(4):290-4 [19319634.001]
  • [Cites] N Engl J Med. 2000 Sep 28;343 (13):905-14 [11006366.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1453-7 [6311394.001]
  • [Cites] Ann Surg Oncol. 2008 Oct;15(10):2684-91 [18649106.001]
  • [Cites] Langenbecks Arch Surg. 2004 Jun;389(3):178-83 [15188084.001]
  • [Cites] Dis Colon Rectum. 1999 Dec;42(12):1618-25 [10613484.001]
  • [Cites] Dis Colon Rectum. 1995 Nov;38(11):1189-92 [7587762.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] ANZ J Surg. 2001 Dec;71(12):703-6 [11906382.001]
  • (PMID = 20180076.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


64. Zaanan A, Cuilliere-Dartigues P, Guilloux A, Parc Y, Louvet C, de Gramont A, Tiret E, Dumont S, Gayet B, Validire P, Fléjou JF, Duval A, Praz F: Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol; 2010 Apr;21(4):772-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.
  • BACKGROUND: The aim was to determine the values of p53 tumour expression and microsatellite instability (MSI) phenotype to predict benefit from adjuvant chemotherapy of colon cancer by 5-fluorouracil and leucovorin (FL) alone or with oxaliplatin (FOLFOX).
  • PATIENTS AND METHODS: This retrospective study included 233 unselected patients with stage III colon cancer treated by FL (n = 124) or FOLFOX (n = 109).
  • CONCLUSION: Our observations indicate that MSI status and p53 expression may influence the impact of oxaliplatin on adjuvant treatment of stage III colon cancer patients.

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19833818.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Tumor Suppressor Protein p53; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


65. Schwandner O, Schlamp A, Broll R, Bruch HP: Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer. Int J Colorectal Dis; 2007 Feb;22(2):127-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inclusion criteria were sporadic rectal adenocarcinoma resected curatively (including total mesorectal excision), adjuvant radiochemotherapy in UICC stages II and III, and complete intra-institutional follow-up.
  • Neither pattern correlated with age, gender, tumor stage (UICC), grading, preoperative serum carcinoembryonic antigen (CEA) level, or nodal status (p>0.05).
  • In terms of survival, preoperative CEA level (disease-free 5-year survival 46% with increased CEA vs 70% with normal CEA, p=0.01; overall 5-year survival 43 vs 74%, p<0.01) and UICC stage were the only factors to be significantly related to 5-year survival by univariate analysis, whereas the metalloproteinases failed to show a significant association.
  • In multivariate analysis, CEA and UICC stage were not identified as independent factors predictive of survival.
  • [MeSH-major] Adenocarcinoma / metabolism. Matrix Metalloproteinase 14 / biosynthesis. Matrix Metalloproteinase 2 / biosynthesis. Matrix Metalloproteinase 7 / biosynthesis. Rectal Neoplasms / metabolism. Tissue Inhibitor of Metalloproteinase-2 / biosynthesis

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 2004;200(5):379-87 [15239346.001]
  • [Cites] Mod Pathol. 1991 Mar;4(2):239-46 [1646457.001]
  • [Cites] Mod Pathol. 1994 Feb;7(2):220-5 [8008747.001]
  • [Cites] Br J Cancer. 1997;76(6):805-11 [9310250.001]
  • [Cites] Br J Cancer. 2001 May 18;84(10):1317-21 [11355941.001]
  • [Cites] J Korean Med Sci. 1999 Aug;14(4):417-23 [10485622.001]
  • [Cites] Dis Colon Rectum. 1999 May;42(5):559-62 [10344676.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1995 Sep;104(9 Pt 1):678-84 [7661515.001]
  • [Cites] Cancer. 1998 Sep 15;83(6):1153-62 [9740080.001]
  • [Cites] Int J Cancer. 2001 Sep 20;95(5):290-4 [11494227.001]
  • [Cites] Int J Colorectal Dis. 2004 Nov;19(6):518-24 [15103490.001]
  • [Cites] Gut. 1999 Aug;45(2):252-8 [10403738.001]
  • [Cites] Jpn J Clin Oncol. 1996 Oct;26(5):303-9 [8895669.001]
  • [Cites] FASEB J. 1999 May;13(8):781-92 [10224222.001]
  • [Cites] Int J Colorectal Dis. 2005 May;20(3):245-52 [15592677.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):324-9 [9440760.001]
  • [Cites] World J Gastroenterol. 2005 May 28;11(20):3046-50 [15918187.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):215-8 [10901373.001]
  • [Cites] Langenbecks Arch Surg. 1999 Apr;384(2):167-75 [10328170.001]
  • [Cites] Dis Colon Rectum. 1996 Nov;39(11):1255-64 [8918435.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):91-8 [10502432.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3387-91 [16101153.001]
  • [Cites] Matrix Biol. 1997 Mar;15(8-9):535-41 [9138286.001]
  • [Cites] Urology. 1997 Aug;50(2):295-301 [9255309.001]
  • [Cites] Chirurg. 2003 Oct;74(10):905-14 [14605732.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5b):4169-73 [14666620.001]
  • [Cites] Dis Colon Rectum. 2000 Nov;43(11):1606-27 [11089603.001]
  • [Cites] Gut. 2005 Dec;54(12):1751-8 [16284286.001]
  • [Cites] Oncology. 2003;65(4):337-46 [14707454.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):537-43 [12006939.001]
  • [Cites] J Biochem. 1996 Feb;119(2):209-15 [8882706.001]
  • [Cites] Jpn J Clin Oncol. 2005 Dec;35(12):739-44 [16314344.001]
  • (PMID = 16896992.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.80 / Matrix Metalloproteinase 14
  •  go-up   go-down


66. D'Annibale A, Morpurgo E, Fiscon V, Termini B, Serventi A, Sovernigo G, Orsini C: Minimally invasive resection for colorectal cancer: perioperative and medium-term results in an unselected patient group at a single institution. Tech Coloproctol; 2006 Dec;10(4):303-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In the study period, 302 patients (mean age 66.1 years; range, 32-93 years) underwent 114 left hemicolectomies, 108 low anterior resections, 61 right hemicolectomies, 12 Miles procedures, 4 subtotal colectomies, and 3 transverse colon resections.
  • Cancer-related survival curves showed a 90% survival for stage II, 85% for stage III, and 10% for stage IV disease, 30 months after surgery.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery. Laparoscopy. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Tech Coloproctol. 2009 Mar;13(1):103
  • (PMID = 17115319.001).
  • [ISSN] 1123-6337
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


67. Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients. Int Semin Surg Oncol; 2007 Sep 20;4:23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: although preoperative RT (Radiation Therapy) is becoming the preferred approach for combined treatment of locally advanced rectal adenocarcinoma, no regimen can be now considered as a standard.
  • METHODS: patients were screened following these eligibility criteria: histology-proven adenocarcinoma of the rectum; distal tumour extent at 12 cm or less from the anal verge; clinical stage T3-4/anyN, or anyT/N1-2; ECOG Performance Status 0-2.
  • Twenty-eight patients were stage II and 19 stage III.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1990 Feb;211(2):187-95 [2405793.001]
  • [Cites] Am J Surg. 1994 Jan;167(1):90-4; discussion 94-5 [8311145.001]
  • [Cites] Ann Surg. 1998 Feb;227(2):157-67 [9488510.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):388-96 [10699069.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):633-40 [11685026.001]
  • [Cites] Lancet. 2000 Jul 8;356(9224):93-6 [10963244.001]
  • [Cites] Ann Surg. 1994 Nov;220(5):676-82 [7979617.001]
  • [Cites] Br J Radiol. 1989 Aug;62(740):679-94 [2670032.001]
  • [Cites] Strahlenther Onkol. 2002 May;178(5):259-62 [12082685.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):964-8 [8813788.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):67-73 [7826163.001]
  • [Cites] Dis Colon Rectum. 1992 Aug;35(8):757-61 [1643999.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 May;10(5):593-8 [6735750.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2396 [10561302.001]
  • [Cites] Strahlenther Onkol. 2004 Jan;180(1):5-14 [14704839.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):387-92 [1587760.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1291-304 [11684209.001]
  • [Cites] Clin Radiol. 1971 Apr;22(2):145-55 [5575251.001]
  • (PMID = 17883838.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2063497
  •  go-up   go-down


68. Ugurlu MM, Asoglu O, Potter DD, Barnes SA, Harmsen WS, Donohue JH: Adenocarcinomas of the jejunum and ileum: a 25-year experience. J Gastrointest Surg; 2005 Nov;9(8):1182-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because few large published experiences exist, we reviewed patients with jejunal and ileal adenocarcinoma treated at our institution over the last 25 years.
  • Between January 1976 and December 2001, 77 patients had an operation for a jejunal or ileal adenocarcinoma.
  • One (1%) patient had stage I, 18 (23%) stage II, 19 (25%) stage III, and 39 (51%) stage IV adenocarcinoma at diagnosis.
  • Tumor stage had a highly significant effect (P < 0.0001) on median survival (72 months for stage I and II, 30 months for stage III, and 9 months for stage IV disease).
  • In multivariate analysis of patients having curative treatment, tumor recurrence (P < 0.0001), stage (P < 0.0002), and weight loss (P < 0.001) were significant negative prognostic indicators.
  • Most patients with adenocarcinoma of the jejunum or ileum present with advanced disease.
  • Tumor stage, disease recurrence, and weight loss predicted patient outcome following a curative operation.
  • [MeSH-major] Adenocarcinoma / surgery. Ileal Neoplasms / surgery. Jejunal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] Inflamm Bowel Dis. 2004 Jan;10(1):32-5 [15058524.001]
  • [Cites] J Gastrointest Surg. 2003 Nov;7(7):925-30 [14592670.001]
  • [Cites] J Clin Gastroenterol. 2001 Oct;33(4):267-82 [11588539.001]
  • [Cites] Am J Surg. 1986 Jun;151(6):654-8 [2424326.001]
  • [Cites] Ann Surg Oncol. 1994 May;1(3):183-8 [7842287.001]
  • [Cites] Arch Surg. 2002 May;137(5):564-70; discussion 570-1 [11982470.001]
  • [Cites] Chin Med J (Engl). 2004 Jul;117(7):1045-9 [15265380.001]
  • [Cites] Am J Surg. 1997 Mar;173(3):237-9 [9124635.001]
  • [Cites] Arch Surg. 2000 Jun;135(6):635-41; discussion 641-2 [10843358.001]
  • [Cites] Semin Oncol. 1988 Apr;15(2):116-28 [3285475.001]
  • [Cites] Gastroenterology. 1985 Aug;89(2):438-41 [4007431.001]
  • [Cites] Ann Surg. 1997 Mar;225(3):300-6 [9060587.001]
  • [Cites] J Chemother. 2003 Oct;15(5):503-6 [14598944.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] Ann Surg Oncol. 1994 Jul;1(4):290-5 [7850527.001]
  • [Cites] Am Surg. 2000 Jan;66(1):46-51 [10651347.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1496-502 [12432298.001]
  • (PMID = 16269390.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Sträter J, Herter I, Merkel G, Hinz U, Weitz J, Möller P: Expression and prognostic significance of APAF-1, caspase-8 and caspase-9 in stage II/III colon carcinoma: caspase-8 and caspase-9 is associated with poor prognosis. Int J Cancer; 2010 Aug 15;127(4):873-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic significance of APAF-1, caspase-8 and caspase-9 in stage II/III colon carcinoma: caspase-8 and caspase-9 is associated with poor prognosis.
  • To study their prognostic influence in colon carcinoma, expression of APAF-1, caspase-8 and caspase-9 was determined by immunohistochemistry in normal colon mucosa (n = 8) and R0-resected stage II/III colon carcinomas (n >or= 124) using a semiquantitative score.
  • In normal colon, APAF-1 and caspase-8 are most strongly expressed in the luminal surface epithelium, whereas caspase-9 is expressed all along the crypt axis.
  • In colon carcinomas, there is considerable variability in the expression of these proapoptotic factors, although complete loss of caspase-8 and caspase-9 is rare.
  • The influence of caspase-8 expression was mainly seen in patients with stage III colon carcinoma (p = 0.011), whereas the prognostic influence of caspase-9 expression was significant in stage II cases (p = 0.037) and just failed to be significant in stage III tumors (p = 0.0581).
  • Our data suggest that, in colon carcinomas, expression of caspase-8 and caspase-9 is significantly associated with poor survival.
  • Caspase-9 may be an independent prognosticator in colon carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Apoptotic Protease-Activating Factor 1 / metabolism. Biomarkers, Tumor / metabolism. Caspase 8 / metabolism. Caspase 9 / metabolism. Colonic Neoplasms / metabolism
  • [MeSH-minor] Aged. Colon / metabolism. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20013803.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / APAF1 protein, human; 0 / Apoptotic Protease-Activating Factor 1; 0 / Biomarkers, Tumor; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9
  •  go-up   go-down


70. Dahl O: [Adjuvant chemotherapy for colon cancer]. Tidsskr Nor Laegeforen; 2007 Nov 29;127(23):3094-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant chemotherapy for colon cancer].
  • BACKGROUND: Radical resection is the main treatment for adenocarcinoma of the colon.
  • The background for adjuvant chemotherapy of colon cancer is presented.
  • RESULTS AND INTERPRETATION: Cure rates after curative resections of colon cancer (stage III) are improved by about 12% if patients are treated with adjuvant chemotherapy with oxaliplatin combined with 5-fluoruracil and folinat (or capecitabine) for 6 months.
  • Certain subgroups of stage II (Dukes' stage B) are also likely to benefit from adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Colonic Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18049502.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents
  • [Number-of-references] 35
  •  go-up   go-down


71. López-Cano M, Mañas MJ, Hermosilla E, Espín E: Multivisceral resection for colon cancer: analysis of prognostic factors. Dig Surg; 2010 Aug;27(3):238-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multivisceral resection for colon cancer: analysis of prognostic factors.
  • BACKGROUND/AIMS: To assess outcome of multivisceral resection in colon cancer patients and to identify predictors of survival.
  • METHODS: One hundred and thirteen consecutive patients with primary locally advanced colon cancer infiltrating adjacent organs undergoing multivisceral resection between 1998 and 2007 were reviewed.
  • The diagnosis was conventional adenocarcinoma in 94 patients.
  • Hematochezia and adjuvant chemotherapy were independent factors of favorable outcome and grade G3 and tumor stage III-IV of poor survival.
  • CONCLUSION: Hematochezia and adjuvant chemotherapy were associated with a better survival, and poorly differentiated tumors and stage IV disease with a poor survival.
  • [MeSH-minor] Abdomen, Acute. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Gastrointestinal Hemorrhage / complications. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20571272.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


72. Martínek L, Dostalík J, Gunka I, Gunková P, Vávra P: [Comparison of oncological outcomes between laparoscopic and open procedures in non-metastazing colonic carcinomas]. Rozhl Chir; 2009 Dec;88(12):725-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: The aim of our study was to compare oncological results of laparoscopic assisted coloctomy and open colectomy in the treatment of nonmetastatic colon cancer.
  • MATERIAL AND METHODS: In this prospective nonrandomised clinical trail a group of elective laparoscopic or open resections in patients with the colon adenocarcinom was evaluated in the period between January 2001 and December 2006.
  • With a respect of the tumor stage, there was a tendency of higher overall survival in favour of the laparoscopic group in the stage III, however the difference was not statistically significant (p = 0.07).
  • CONCLUSION: Long-term results support laparoscopic colon cancer surgery as a safe and effective alternative to open surgery.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery. Laparoscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20662437.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


73. Bachet JB, Rougier P, de Gramont A, André T: [Rectal cancer and adjuvant chemotherapy: which conclusions?]. Bull Cancer; 2010 Jan;97(1):107-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Cancer du rectum et chimiothérapie adjuvante: quelles conclusions?
  • Adenocarcinoma of the rectum represents about a third of cases of colorectal cancer, with an annual incidence of 12,000 cases in France.
  • On the contrary of colon cancer, the benefice of adjuvant chemotherapy in rectal cancer has not been definitively proved, more because this question was assessed in few recent studies than because negative results.
  • The data of the "historical studies" of adjuvant treatment in rectal cancer published before 1990, of the meta-analysis of adjuvant trials in rectal cancer and of the QUASAR study suggest that adjuvant chemotherapy with fluoropyrimidines (intravenous or oral), in absence of pre-operative treatment, decrease the risk of metastatic relapse after curative surgery for a rectal cancer of stage II or III.
  • This benefice seems similar to the one observed in colon cancer.
  • The French recommendations are to discuss the indication of adjuvant chemotherapy by fluoropyrimidines in cases of stage III rectal cancer on histopathologic reports and no chemotherapy in case of stade II.
  • Despite the fact that none study have assessed a combination of fluoropyrimidines and oxaliplatin in adjuvant setting in rectal cancer, like in colon cancer, the Folfox4, modified Folfox6 or Xelox regimens are valid options in stage III (experts opinion).
  • [MeSH-major] Adenocarcinoma / drug therapy. Rectal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19965305.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 58
  •  go-up   go-down


74. Nabeshima K, Machimura T, Wasada M, Takayasu H, Ogoshi K, Makuuchi H: A case of primary jejunal cancer diagnosed by preoperative small intestinal endoscopy. Tokai J Exp Clin Med; 2008 Apr;33(1):42-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biopsy suggested a well-differentiated adenocarcinoma.
  • Under a diagnosis of primary jejunum cancer, Partial resection of the jejunum and partial resection of the transverse colon was performed.
  • Histopathologically, the tumor was well differentiated adenocarcinoma exposed serosal surface.
  • Postoperatively, the stage was evaluated as III (T3, N1, M0).
  • [MeSH-major] Adenocarcinoma / pathology. Endoscopy, Gastrointestinal. Intestine, Small / pathology. Jejunal Neoplasms / pathology. Preoperative Care

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21318964.001).
  • [ISSN] 2185-2243
  • [Journal-full-title] The Tokai journal of experimental and clinical medicine
  • [ISO-abbreviation] Tokai J. Exp. Clin. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


75. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, Yeatman T, Coppola D, Chen J: SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem; 2009 Jul 3;284(27):18210-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SirT1 is an inhibitor of proliferation and tumor formation in colon cancer.
  • Immunohistochemical staining revealed high level SirT1 in normal colon mucosa and benign adenomas.
  • SirT1 overexpression was observed in approximately 25% of stage I/II/III colorectal adenocarcinomas but rarely found in advanced stage IV tumors.
  • These results suggest a rationale for the use of SirT1 activators and inhibitors in the prevention and treatment of colon cancer.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 17;403(6771):795-800 [10693811.001]
  • [Cites] Science. 2000 Sep 22;289(5487):2126-8 [11000115.001]
  • [Cites] Nature. 2001 Mar 8;410(6825):227-30 [11242085.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • [Cites] Nature. 2003 Sep 11;425(6954):191-6 [12939617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10794-9 [12960381.001]
  • [Cites] Cell. 2004 Feb 20;116(4):551-63 [14980222.001]
  • [Cites] EMBO J. 2004 Jun 16;23(12):2369-80 [15152190.001]
  • [Cites] Science. 2004 Jul 16;305(5682):390-2 [15205477.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5947-52 [7954427.001]
  • [Cites] Nature. 2005 Mar 3;434(7029):113-8 [15744310.001]
  • [Cites] Cell Metab. 2005 Jul;2(1):67-76 [16054100.001]
  • [Cites] Cell Metab. 2005 Aug;2(2):105-17 [16098828.001]
  • [Cites] Cell. 2005 Nov 4;123(3):437-48 [16269335.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10457-63 [16288037.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):28-38 [16354677.001]
  • [Cites] Oncogene. 2006 Jan 12;25(2):176-85 [16170353.001]
  • [Cites] PLoS Biol. 2006 Feb;4(2):e31 [16366736.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4368-77 [16618762.001]
  • [Cites] Nat Cell Biol. 2006 Sep;8(9):1025-31 [16892051.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8122-35 [16923962.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):337-42 [17086191.001]
  • [Cites] Cell. 2006 Dec 15;127(6):1109-22 [17112576.001]
  • [Cites] Mol Cell. 2007 Feb 23;25(4):543-57 [17317627.001]
  • [Cites] Arch Dermatol Res. 2007 May;299(2):103-6 [17180656.001]
  • [Cites] Mol Cell. 2007 Jul 6;27(1):149-62 [17612497.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6612-8 [17638871.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5489-504 [17694089.001]
  • [Cites] Biochem J. 2007 Nov 1;407(3):451-60 [17620057.001]
  • [Cites] Biotechnol J. 2007 Nov;2(11):1360-8 [17806102.001]
  • [Cites] Nature. 2007 Nov 29;450(7170):712-6 [18046409.001]
  • [Cites] Mol Biol Cell. 2008 Mar;19(3):1210-9 [18184747.001]
  • [Cites] PLoS One. 2008;3(4):e2020 [18414679.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):312-23 [18835033.001]
  • (PMID = 19433578.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112215; United States / NCI NIH HHS / CA / R01 CA112215-03; United States / NCI NIH HHS / CA / CA121291; United States / NCI NIH HHS / CA / R01 CA121291; United States / NCI NIH HHS / CA / CA112215-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Small Interfering; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2709385
  •  go-up   go-down


76. Chang SC, Lin JK, Lin TC, Liang WY: Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma. Int J Oncol; 2005 Jan;26(1):65-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
  • Of these, 20 were stage I (12%), 54 stage II (32.3%), 58 stage III (34.7%), and 35 stage IV (21%).
  • Genetic p53 alterations were associated with advanced tumor stage and tumor differentiation.
  • Of 132 potentially cured patients, 3-year disease-free survival (DFS) was affected by: advanced TNM stage (I, II, III: 90%, 84%, and 41%), genetic p53 alteration (89% vs. 43%), intratumoral p53 accumulation (71% vs. 56%), and preoperative CEA level >5 ng/ml (74% vs. 58%).
  • In multivariate analysis, genetic alteration of p53 was the most significant independent prognostic factor [hazard ratio (HR) = 6.09; 95% confidence interval (CI): 2.45-15.11], followed by advanced tumor stage (HR = 3.93; 95% CI: 2.14-7.23), and preoperative CEA >5 ng/ml (HR = 1.98; 95% CI: 1.12-3.17).
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / genetics. Colorectal Neoplasms / diagnosis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15586226.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


77. Jung SH, Kim HC, Yu CS, Chang HM, Ryu MH, Lee JL, Kim JS, Kim JC: [Clinicopathologic characteristics of colorectal neuroendocrine tumor]. Korean J Gastroenterol; 2006 Aug;48(2):97-103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nine tumors were located in the rectum, two in the sigmoid, and each one in the transverse colon and cecum, respectively.
  • All patients were advanced at the time of diagnosis, with AJCC TNM staging: stage IIIB (n=2), stage IIIC (n=3), and stage IV (n=8).
  • Five patients who received chemotherapy showed median survival of 32 months (stage III) and 17.5 months (stage IV), whereas other five patients without chemotherapy died with a median survival of 6.2 months.
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biomarkers, Tumor / immunology. Biopsy. Chromogranin A / analysis. Chromogranin A / immunology. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / mortality. Sigmoid Neoplasms / pathology. Synaptophysin / analysis. Synaptophysin / immunology

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929153.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Synaptophysin
  •  go-up   go-down


78. Suh KW, Kim JH, Kim YB, Kim J, Jeong S: Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer. J Gastrointest Surg; 2005 Mar;9(3):336-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer.
  • Here, we determined the significance of this polymorphism in predicting the clinical outcomes for patients with colon cancer.
  • We reviewed 121 consecutive patients with stage II or III colon cancer who underwent a curative resection.
  • The difference was particularly significant in the patients with stage III disease (41% versus 77%, P=0.0414).
  • Tumor stage and the TS polymorphism were identified as significant prognostic factors by multivariate analysis.
  • We found the TS polymorphism to be a significant and independent prognostic factor for colon cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / mortality. Biomarkers, Tumor / analysis. Colonic Neoplasms / genetics. Colonic Neoplasms / mortality. Thymidylate Synthase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2001 Dec;24(6):597-602 [11801762.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1227-34 [9607581.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3A):1515-20 [9673363.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3223-9 [9336359.001]
  • [Cites] Clin Colorectal Cancer. 2001 Nov;1(3):175-8; discussion 179-81 [12450432.001]
  • [Cites] Biochim Biophys Acta. 1993 Dec 14;1216(3):409-16 [8268221.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1063-72 [10741735.001]
  • [Cites] Pharmacogenomics J. 2001;1(1):65-70 [11913730.001]
  • [Cites] Biochim Biophys Acta. 1977 Dec 23;473(2):73-92 [145246.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):14-20 [7677801.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1407-12 [7882343.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1653-64 [3049954.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):70-7 [9428481.001]
  • [Cites] Nature. 1957 Mar 30;179(4561):663-6 [13418758.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2898-904 [12782596.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1243-50 [9607583.001]
  • [Cites] Cancer Lett. 2003 Feb 10;190(1):97-104 [12536082.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1378-84 [10778966.001]
  • [Cites] Cell Struct Funct. 1995 Jun;20(3):191-7 [7586009.001]
  • [Cites] N Engl J Med. 2001 Apr 19;344(16):1196-206 [11309634.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2832-43 [12065560.001]
  • (PMID = 15749593.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


79. Sträter J, Hinz U, Hasel C, Bhanot U, Mechtersheimer G, Lehnert T, Möller P: Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut; 2005 May;54(5):661-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease.
  • BACKGROUND: Loss of CD95 expression in tumour cells occurs frequently in colon carcinoma and may be associated with disease progression.
  • AIMS: We aimed at further exploring the functional role and prognostic significance of the CD95/CD95L death inducing system in colon carcinomas.
  • PATIENTS AND METHODS: CD95 and CD95L expression was examined by immunohistochemistry in 128 R0 resected UICC (International Union against Cancer) stage II/III colon carcinomas and correlated with disease free survival.
  • Tumour infiltrating lymphocytes (TIL) were the major source of CD95L in colon carcinomas.
  • Moreover, a high rate of CD95L+TIL correlated with prolonged disease free survival in patients with UICC stage II (p = 0.05) but not in those with stage III.
  • CONCLUSIONS: Loss of CD95 in tumour cells may be an independent prognostic factor in colon carcinomas.
  • The CD95L counterattack is not a relevant feature in colon carcinoma but CD95L+TIL may contribute to tumour control in the early stages of the disease, exerting a concurrent selection pressure in the direction of CD95 abrogation/resistance.
  • [MeSH-major] Adenocarcinoma / immunology. Antigens, CD95 / metabolism. Biomarkers, Tumor / metabolism. Colonic Neoplasms / immunology. Membrane Glycoproteins / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Nov;30(11):1309-13 [10571510.001]
  • [Cites] Cell Death Differ. 2001 Mar;8(3):273-8 [11319610.001]
  • [Cites] J Immunol. 2000 May 15;164(10):5023-7 [10799856.001]
  • [Cites] J Pathol. 2001 May;194(1):15-9 [11329136.001]
  • [Cites] J Immunol. 2001 Aug 15;167(4):2068-73 [11489989.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):139-48 [12204534.001]
  • [Cites] J Immunol. 2003 Jun 15;170(12):5973-80 [12794124.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):708-15 [12949717.001]
  • [Cites] J Immunol. 2003 Oct 15;171(8):4164-74 [14530339.001]
  • [Cites] Cancer. 1981 Mar 1;47(5):930-6 [7226044.001]
  • [Cites] Cell. 1991 Jul 26;66(2):233-43 [1713127.001]
  • [Cites] J Biol Chem. 1992 May 25;267(15):10709-15 [1375228.001]
  • [Cites] Lab Invest. 1993 Oct;69(4):415-29 [7693996.001]
  • [Cites] Int J Cancer. 1994 May 1;57(3):371-7 [8168998.001]
  • [Cites] Int J Cancer. 1996 Sep 4;67(5):709-14 [8782663.001]
  • [Cites] Science. 1996 Nov 22;274(5291):1363-6 [8910274.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):1075-82 [9064324.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):1149-54 [9064331.001]
  • [Cites] Cell. 1997 Feb 7;88(3):355-65 [9039262.001]
  • [Cites] Gastroenterology. 1997 Jul;113(1):160-7 [9207274.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):526-34 [9458101.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3491-4 [9721846.001]
  • [Cites] J Exp Med. 1998 Nov 2;188(9):1717-23 [9802983.001]
  • [Cites] J Pathol. 1998 Nov;186(3):240-6 [10211111.001]
  • [Cites] J Exp Med. 1999 Oct 4;190(7):1025-32 [10510092.001]
  • [Cites] J Exp Med. 1999 Oct 4;190(7):1033-8 [10510093.001]
  • [Cites] J Immunol. 2000 May 1;164(9):4941-54 [10779805.001]
  • (PMID = 15831912.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Ligands; 0 / Membrane Glycoproteins
  • [Other-IDs] NLM/ PMC1774512
  •  go-up   go-down


80. Hill DA, Furman WL, Billups CA, Riedley SE, Cain AM, Rao BN, Pratt CB, Spunt SL: Colorectal carcinoma in childhood and adolescence: a clinicopathologic review. J Clin Oncol; 2007 Dec 20;25(36):5808-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: We reviewed the clinical and pathologic features, prognostic factors, and outcome of CRC in 77 children and adolescents (ages 7 to 19 years) referred to St Jude Children's Research Hospital between 1964 and 2003.
  • Tumors were evenly distributed between the right and left colon; 62% were mucinous adenocarcinoma.
  • At presentation, 86% of patients had advanced-stage disease; more than half had distant metastases.
  • Advanced stage and mucinous histology were significant predictors of adverse outcome.
  • Stage-specific survival at 10 years was 67% +/- 27% (stage 1), 38% +/- 15% (stage 2), 28% +/- 11% (stage III), and 7% +/- 4% (stage 4).
  • Although no patient had a diagnosis of polyposis syndrome before diagnosis of CRC, 17 (22%) had colon polyps and eight (including two who previously underwent pelvic radiotherapy) had multiple polyps.
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / therapy. Adolescent. Adult. Child. Cohort Studies. Female. Humans. Male. Prognosis. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089879.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA23099
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


81. Paduch R, Kandefer-Szerszeń M: Transforming growth factor-beta1 (TGF-beta1) and acetylcholine (ACh) alter nitric oxide (NO) and interleukin-1beta (IL-1beta) secretion in human colon adenocarcinoma cells. In Vitro Cell Dev Biol Anim; 2009 Oct;45(9):543-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transforming growth factor-beta1 (TGF-beta1) and acetylcholine (ACh) alter nitric oxide (NO) and interleukin-1beta (IL-1beta) secretion in human colon adenocarcinoma cells.
  • Colon adenocarcinoma is one of the most common fatal malignancies in Western countries.
  • The present study was conducted to assess the influence of recombinant human transforming growth factor (rhTGF)-beta1 or ACh on nitric oxide (NO) and interleukin-1beta (IL-1beta) secretion by three human colon adenocarcinoma cell lines: HT29, LS180, and SW948, derived from different grade tumors (Duke's stage).
  • Colon carcinoma cells exhibited different sensitivities to rhTGF-beta1 or ACh dependent on the tumor grade and the culture model.
  • ACh exhibited significant inhibitory effects towards NO, endothelial nitric oxide synthase (eNOS), and IL-1beta secretion especially by tumor cells derived form Duke's C stage of colon carcinoma. rhTGF-beta1 also decreased NO, IL-1beta, and eNOS expression, but its effect was lower than that observed after the administration of ACh.
  • Taken together, the TGF-beta1-ACh axis may regulate colon carcinoma progression and metastasis by altering NO secretion and influence inflammatory responses by modulating IL-1beta production.
  • [MeSH-minor] Cell Line, Tumor. Enzyme-Linked Immunosorbent Assay. Humans. Nitric Oxide Synthase Type III / metabolism

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biol Markers. 2005 Oct-Dec;20(4):235-41 [16398405.001]
  • [Cites] Gastroenterology. 1996 Feb;110(2):375-82 [8566583.001]
  • [Cites] Cell Biol Int. 2005 Jul;29(7):497-505 [15893483.001]
  • [Cites] World J Surg. 2005 Mar;29(3):306-11 [15711891.001]
  • [Cites] Cancer Metastasis Rev. 2006 Sep;25(3):387-408 [17043764.001]
  • [Cites] Baillieres Clin Haematol. 1992 Jul;5(3):703-21 [1333850.001]
  • [Cites] Med Hypotheses. 2008;70(1):43-51 [17587508.001]
  • [Cites] Clin Immunol. 2002 Feb;102(2):169-78 [11846459.001]
  • [Cites] Biochem Pharmacol. 2004 Jun 15;67(12):2197-205 [15163551.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6744-50 [14583469.001]
  • [Cites] J Am Coll Cardiol. 1997 Feb;29(2):308-17 [9014982.001]
  • [Cites] Br J Cancer. 1996 Dec;74(12):1955-60 [8980396.001]
  • [Cites] Eur J Cancer. 2000 Jun;36(10):1288-91 [10882868.001]
  • [Cites] Lancet Oncol. 2001 Mar;2(3):149-56 [11902565.001]
  • [Cites] Clin Exp Metastasis. 1997 Nov;15(6):557-67 [9344040.001]
  • [Cites] Dig Dis Sci. 1999 May;44(5):916-21 [10235597.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 May;129(5):272-8 [12748850.001]
  • [Cites] Int J Mol Med. 2002 Jun;9(6):651-7 [12011984.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(2):224-33 [11166150.001]
  • [Cites] Ann Med. 1995 Jun;27(3):359-67 [7546626.001]
  • [Cites] Mutat Res. 2004 Nov 2;555(1-2):107-19 [15476855.001]
  • [Cites] Drug Resist Updat. 2006 Jun;9(3):157-73 [16822706.001]
  • [Cites] Clin Exp Metastasis. 2005;22(4):341-9 [16170670.001]
  • [Cites] Gastroenterology. 1995 Aug;109(2):483-9 [7615197.001]
  • [Cites] Med Hypotheses. 2007;69(6):1272-6 [17553629.001]
  • [Cites] Cancer Immunol Immunother. 2004 Aug;53(8):723-8 [15034673.001]
  • [Cites] Inflamm Res. 2004 Feb;53(2):60-5 [15021970.001]
  • [Cites] Life Sci. 2003 Mar 28;72(18-19):2159-68 [12628474.001]
  • [Cites] J Transl Med. 2006 Nov 10;4:48 [17096856.001]
  • (PMID = 19551451.001).
  • [ISSN] 1543-706X
  • [Journal-full-title] In vitro cellular & developmental biology. Animal
  • [ISO-abbreviation] In Vitro Cell. Dev. Biol. Anim.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Interleukin-1beta; 0 / Transforming Growth Factor beta1; 31C4KY9ESH / Nitric Oxide; EC 1.14.13.39 / Nitric Oxide Synthase Type III; N9YNS0M02X / Acetylcholine
  •  go-up   go-down


82. Huerta S, Heinzerling JH, Anguiano-Hernandez YM, Huerta-Yepez S, Lin J, Chen D, Bonavida B, Livingston EH: Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF. J Surg Res; 2007 Sep;142(1):184-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF.
  • BACKGROUND: Colon cancer becomes resistant to apoptosis as it acquires metastatic potential.
  • SW480 and SW620 colon cancer cells were established from the same patient at different stages of tumor progression.
  • The stage III colorectal cancer cell line (SW620) is more resistant to apoptosis.
  • In the present report, we investigated the apoptotic gene products that might account for colon cancer evasion of immune attack and chemoradioresistance-induced apoptosis.
  • CONCLUSIONS: SW620 cells have acquired genetic defects both in the intrinsic and extrinsic pathways of apoptosis, which may explain in part the ability of colon cancer cells to escape the immune system and to become chemoradioresistant.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / physiopathology. Antibodies / pharmacology. Antineoplastic Agents / pharmacology. Apoptosomes / physiology. Cell Line, Tumor. Cisplatin / pharmacology. Colon / drug effects. Colon / pathology. Colon / radiation effects. Colonic Neoplasms / pathology. Colonic Neoplasms / physiopathology. Disease Progression. Gene Expression Regulation, Neoplastic. Humans. Neoplasm Metastasis / physiopathology. Proto-Oncogene Proteins c-bcl-2 / physiology. Receptors, Death Domain / physiology. Tumor Suppressor Protein p53 / physiology

  • Genetic Alliance. consumer health - Metastatic cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17603079.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / APAF1 protein, human; 0 / Antibodies; 0 / Antigens, CD95; 0 / Antineoplastic Agents; 0 / Apoptosis Inducing Factor; 0 / Apoptosomes; 0 / Apoptotic Protease-Activating Factor 1; 0 / CH-11 anti-fas antibody, human; 0 / DIABLO protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Mitochondrial Proteins; 0 / NF-kappa B; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Death Domain; 0 / Tumor Suppressor Protein p53; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


83. Brozovich M, Read TE, Salgado J, Akbari RP, McCormick JT, Caushaj PF: Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution. Surg Endosc; 2008 Feb;22(2):506-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) a substantial fraction of patients undergoing laparoscopic colectomy for apparently benign colorectal neoplasia will have adenocarcinoma on final pathology; and (2) in our practice, we perform an adequate laparoscopic oncological resection for apparently benign polyps as evidenced by margin status and nodal retrieval.
  • Invasive adenocarcinoma was found on histological analysis of the colectomy specimen in 14 out of 63 cases (22%), standard error of the proportion 0.052.
  • Staging of the 14 cancers were I (n = 6, 43%), II (n = 3, 21%), III ( = 4, 29%), and IV (n = 1, 7%).
  • Neither dysplasia on endoscopic biopsy nor lesion diameter was predictive of adenocarcinoma.
  • Eight out of 23 (35%) patients with dysplasia on endoscopic biopsy had adenocarcinoma on final pathology versus 6/40 (15%) with no dysplasia (p = 0.114, Fisher's exact test).
  • CONCLUSION: A substantial fraction of endoscopically unresectable colorectal neoplasms with benign histology on initial biopsy will harbor invasive adenocarcinoma, some of advanced stage.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Polyps / surgery. Colorectal Neoplasms / surgery. Laparoscopy

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Am J Surg. 1999 May;177(5):384-7 [10365875.001]
  • [Cites] Ann Surg. 1979 Dec;190(6):679-83 [518167.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1341-4 [9788858.001]
  • [Cites] AORN J. 1992 Dec;56(6):1068-73 [1463326.001]
  • [Cites] Dis Colon Rectum. 2006 Jun;49(6):879-82 [16598402.001]
  • [Cites] Surg Endosc. 2005 Sep;19(9):1252-5 [16132333.001]
  • [Cites] Surg Endosc. 2007 Mar;21(3):400-3 [17180271.001]
  • [Cites] Int J Colorectal Dis. 1997;12(5):267-71 [9401839.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):505-8 [10215825.001]
  • (PMID = 17704872.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


84. Tsai WS, Changchien CR, Yeh CY, Chen JS, Tang R, Chiang JM, Hsieh PS, Fan CW, Wang JY: Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer. Dis Colon Rectum; 2006 Jun;49(6):883-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preoperative plasma vascular endothelial growth factor levels were positively correlated with tumor stage, T class, M class, and tumor size (Spearman correlation, P < 0.01), but were not associated with gender, N class, tumor location, histology type, or grade.
  • The positive rates of vascular endothelial growth factor elevation (>148.6 pg/ml) compared with carcinoembryonic antigen elevation were 36.9 to 14.6 percent in Stage I, 60.9 to 33 percent in Stage II, 62.9 to 48.7 percent in Stage III, and 86 to 70.2 percent in Stage IV, respectively.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / pathology. Colorectal Neoplasms / blood. Colorectal Neoplasms / pathology. Nitrites / blood. Vascular Endothelial Growth Factor A / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16741643.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nitrites; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


85. Fishman DA, Cohen L, Blank SV, Shulman L, Singh D, Bozorgi K, Tamura R, Timor-Tritsch I, Schwartz PE: The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol; 2005 Apr;192(4):1214-21; discussion 1221-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer.
  • OBJECTIVE: Epithelial ovarian cancer kills more women than all other gynecologic malignancies combined because of our inability to detect early-stage disease.
  • Ultrasonography has demonstrated usefulness in the detection of ovarian cancer in asymptomatic women, but its value for the detection of early-stage epithelial ovarian cancer in women of increased risk is uncertain.
  • We examined the usefulness of sonography in the detection of early-stage epithelial ovarian cancer in asymptomatic high-risk women who participated in the National Ovarian Cancer Early Detection Program.
  • Increased risk includes women with at least 1 affected first-degree relative with ovarian cancer; a personal history of breast, ovarian, or colon cancer; > or =1 affected first- and second-degree relatives with breast and or ovarian cancer; inheritance of a breast cancer mutation from an affected family member, or membership within a recognized cancer syndrome.
  • The detected malignancies were fallopian tube carcinoma (stage IIIC; n = 4 women), primary peritoneal carcinoma (n = 4 women; stage IIIA, 1 woman; stage IIIB, 2 women; stage IIIC, 1 woman), epithelial ovarian cancer (stages IIIA and IIIB; n = 2 women), and endometrial adenocarcinoma (stage IA; n = 2 women).
  • A total of 184 women with genetic predisposition (breast cancer positive) have undergone a prophylactic bilateral salpingo-oophorectomy; 23% of these procedures found atypical hyperplasia, and unexpectedly, 2 women (1%) were found to have stage III (A and B) primary peritoneal carcinoma.
  • CONCLUSION: This study demonstrates the limited value of diagnostic ultrasound examination as an independent modality for the detection of early-stage epithelial ovarian cancer in asymptomatic women who are at increased risk for disease.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15846205.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA83639; United States / NCI NIH HHS / CA / R01 CA01015; United States / NCI NIH HHS / CA / R01 CA82562; United States / NCI NIH HHS / CA / R01 CA89503; United States / NCI NIH HHS / CA / UO1CA85133
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


86. Lim SB, Choi HS, Jeong SY, Park JG: Feasibility of laparoscopic techniques as the surgical approach of choice for primary colorectal cancer: an analysis of 570 consecutive cases. Surg Endosc; 2008 Dec;22(12):2588-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The study times were divided into three periods based on the COST trial report and the time when the laparoscopic technique was accepted as the surgical approach of choice at our center (period I: October 2000 to May 2004, II: June 2004 to December 2005, III: January to December 2006).
  • RESULTS: The use of laparoscopic surgery increased from 2.4% in period I, to 19.2% in period II, to 66.1% in period III.
  • Over the periods, the proportion of rectal cancer and right colon cancer increased (p < 0.001), T- and N-stage became more advanced (p < 0.001, p = 0.011 respectively), and operative time decreased (p < 0.001).
  • The short-term favorable outcomes support the feasibility of laparoscopic technique as surgical approach of choice for colon cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Colorectal Neoplasms / surgery. Laparoscopy / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2010 Mar;24(3):726-7 [19633895.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):477-84 [15992696.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):655-62; discussion 662-4 [17893502.001]
  • [Cites] Surg Endosc. 2003 Apr;17(4):636-40 [12574925.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Arch Surg. 1997 Jan;132(1):41-4; discussion 45 [9006551.001]
  • [Cites] Dis Colon Rectum. 2002 Dec;45(12):1648-54 [12473889.001]
  • [Cites] Surg Endosc. 2004 Oct;18(10):1457-62 [15791369.001]
  • [Cites] Surg Laparosc Endosc. 1991 Sep;1(3):144-50 [1688289.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1111-24 [15449261.001]
  • [Cites] Surg Endosc. 2006 Aug;20(8):1197-202 [16865622.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):83-91 [15973105.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1718-26 [15894098.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3061-8 [17634484.001]
  • [Cites] Ann Oncol. 2006 Aug;17(8):1239-48 [16873440.001]
  • [Cites] Ann Surg. 2002 Dec;236(6):759-66; disscussion 767 [12454514.001]
  • [Cites] Surg Endosc. 2005 Jun;19(6):757-66 [15868256.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):335-42 [12616116.001]
  • [Cites] Colorectal Dis. 2005 Jul;7(4):369-74 [15932561.001]
  • [Cites] Dis Colon Rectum. 1997 May;40(5):592-6 [9152190.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):449-57 [11923599.001]
  • [Cites] Surg Endosc. 2001 Feb;15(2):116-20 [11285950.001]
  • [Cites] Surg Endosc. 2004 Feb;18(2):281-9 [14691716.001]
  • [Cites] Dis Colon Rectum. 1995 Jun;38(6):600-3 [7774470.001]
  • (PMID = 19011948.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


87. Chen HH, Chakravarty K D, Wang JY, Changchien CR, Tang R: Pathological examination of 12 regional lymph nodes and long-term survival in stages I-III colon cancer patients: an analysis of 2,056 consecutive patients in two branches of same institution. Int J Colorectal Dis; 2010 Nov;25(11):1333-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological examination of 12 regional lymph nodes and long-term survival in stages I-III colon cancer patients: an analysis of 2,056 consecutive patients in two branches of same institution.
  • PURPOSE: Pathologic examination of at least 12 lymph nodes (LNs) is widely accepted as a standard for colon cancer surgery.
  • METHODS: Patients with stages I-III adenocarcinoma of the colon between 1998 and 2003 were identified from the Chang Gung Colorectal Tumor Registry in two branches (Linkou and Kaohsiung branches) of same institution.
  • Younger age, right hemicolectomy, larger tumor, higher tumor stage, higher caseload of surgeons, and patients at Linkou branch with an odds ratio (OR) as high as 23 (95% CI, 17-31) were independently associated with a higher frequency of ≥12 examined nodes.
  • Patients with examined node number of <12 had a greater risk of recurrence within stages II and III (stage II: adjusted OR 1.88, 95% CI 1.27-2.79; stage III: adjusted OR 1.58, 95% CI 1.15-2.17) but not within stage I (OR 0.73, 95% CI 0.23-2.24).
  • CONCLUSIONS: The results confirm that factors influencing nodal harvest are multifactorial and the examined LN number of 12 or more is associated with an increased long-term survival in stages II-III colon cancer.
  • It is possible to adequately sample and examine a sufficient number of nodes in the majority of colon cancer specimens by standardized conventional methods.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Dec 22;353(25):2654-66 [16371631.001]
  • [Cites] Ann N Y Acad Sci. 2000 Jun;910:62-73; discussion 73-4 [10911906.001]
  • [Cites] Dis Colon Rectum. 2009 Feb;52(2):260-7 [19279421.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2896-900 [10561368.001]
  • [Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308 [15537574.001]
  • [Cites] Ann Surg. 2009 Apr;249(4):602-7 [19300229.001]
  • [Cites] J Gastroenterol Hepatol. 1991 Jul-Aug;6(4):325-44 [1912440.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):666-72 [9708929.001]
  • [Cites] Ann Surg. 2007 Jun;245(6):858-63 [17522509.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Ann Surg. 2007 Jun;245(6):846-57 [17522508.001]
  • [Cites] Colorectal Dis. 2008 Feb;10(2):157-64 [17477849.001]
  • [Cites] N Engl J Med. 1985 Jun 20;312(25):1604-8 [4000199.001]
  • [Cites] Ann Surg Oncol. 2009 Mar;16(3):585-93 [19116751.001]
  • [Cites] J Gastrointest Surg. 2002 Nov-Dec;6(6):883-88; discussion 889-90 [12504228.001]
  • [Cites] J Clin Oncol. 2009 Dec 20;27(36):6166-71 [19901106.001]
  • [Cites] Am J Surg. 2007 Sep;194(3):349-54 [17693281.001]
  • [Cites] Arch Surg. 2008 Nov;143(11):1050-5; discussion 1055 [19015462.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(2):272-9 [15661553.001]
  • [Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):433-41 [17374833.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):624-8; discussion 628-30 [15383790.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2912-9 [12885809.001]
  • [Cites] JAMA. 2007 Nov 14;298(18):2149-54 [18000198.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):46-51 [17985187.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):213-8 [12679304.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):452 [11466702.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8706-12 [16314630.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):682-7 [8608876.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):878-83 [16418493.001]
  • [Cites] J Am Coll Surg. 2008 Feb;206(2):247-54 [18222376.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71 [12513963.001]
  • [Cites] Arch Surg. 2010 Jan;145(1):12-7 [20083749.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):458-63 [11923600.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):179-89 [11812939.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(14):2071-8 [16125926.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):219-25 [15687365.001]
  • (PMID = 20676662.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


88. Fujita S, Yamamoto S, Akasu T, Moriya Y, Taniguchi H, Shimoda T: Quantification of CD10 mRNA in colorectal cancer and relationship between mRNA expression and liver metastasis. Anticancer Res; 2007 Sep-Oct;27(5A):3307-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TIN was higher in colon, pN1/pN2, stage III and IV, and well- or moderately-differentiated adenocarcinoma than in rectum, pNO, stage I and II, and poorly-differentiated or mucinous adenocarcinoma, respectively.
  • Although CD10 mRNA was associated with invasion depth, lymph node status and TNM stage, it was not associated with prognosis.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / immunology. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Female. Humans. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction


89. Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thödtmann R, Tschmelitsch J, Jagoditsch M, Steger GG, Jakesz R, Herbst F, Hofbauer F, Rabl H, Wohlmuth P, Gnant M, Thaler J, Austrian Breast and Colorectal Cancer Study Group: A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer; 2007 Oct 22;97(8):1021-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
  • The purpose of this trial was to investigate the efficacy of adjuvant chemotherapy with 5-fluorouracil (5-FU) and leucovorin (LV) in stage II colon cancer.
  • Patients with stage II colon cancer were randomised to either adjuvant chemotherapy with 5-FU/LV (100 mg m(-2) LV+450 mg m(-2) 5-FU weekly, weeks 1-6, in 8 weeks cycles x 7) or surveillance only.
  • In conclusion, results of this trial demonstrate a trend to a lower risk for relapse in patients treated with adjuvant 5-FU/LV for stage II colon cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Neoplasm Recurrence, Local / prevention & control

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3553-9 [10550154.001]
  • [Cites] Ann Surg. 2006 Oct;244(4):602-10 [16998369.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2912-9 [12885809.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3395-407 [15199087.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Biometrics. 1975 Mar;31(1):103-15 [1100130.001]
  • [Cites] J Natl Cancer Inst. 1988 Mar 2;80(1):30-6 [3276901.001]
  • [Cites] Arch Surg. 1989 Feb;124(2):180-2 [2916939.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1466-75 [2202789.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • (PMID = 17895886.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2360441
  •  go-up   go-down


90. Preis M, Korc M: Kinase signaling pathways as targets for intervention in pancreatic cancer. Cancer Biol Ther; 2010 May 15;9(10):754-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer related mortality in the United States.
  • The prognosis of patients with PDAC is extremely poor with a median survival of 6 months, in part due to the advanced stage at the time of diagnosis and early metastatic spread.
  • The relatively recent introduction of novel therapies targeting tyrosine kinase and serine/threonine kinase pathways have yielded dramatic results in certain hematological malignancies, and have resulted in significant advances in our ability to treat patients with melanoma, breast, lung and colon cancer, thereby leading to improved survival and quality of life.
  • Thus, despite encouraging phase I/II studies, the vast majority of phase-III studies have failed to demonstrate improved efficacy in PDAC.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20234186.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-R37-75059
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hedgehog Proteins; EC 2.7.- / Phosphotransferases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


91. Wille-Jørgensen P, Laurberg S, Påhlman L, Carriquiry L, Lundqvist N, Smedh K, Svanfeldt M, Bengtson J: An interim analysis of recruitment to the COLOFOL trial. Colorectal Dis; 2009 Sep;11(7):756-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: Prospective registration of all operated patients as well as inclusions (curative resection, stage II or III disease, <or= 75 years, clean colon and exclusions of the individual patients in eight participating departments.
  • [MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Patient Selection. Rectal Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19708095.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  •  go-up   go-down


92. Fazeli MS, Adel MG, Lebaschi AH: Colorectal carcinoma: a retrospective, descriptive study of age, gender, subsite, stage, and differentiation in Iran from 1995 to 2001 as observed in Tehran University. Dis Colon Rectum; 2007 Jul;50(7):990-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal carcinoma: a retrospective, descriptive study of age, gender, subsite, stage, and differentiation in Iran from 1995 to 2001 as observed in Tehran University.
  • These factors also are evaluated in conjunction with disease stage and tumor differentiation at the time of diagnosis.
  • METHODS: Data from 419 patients from a population that receives no screening between April 1995 and March 2001 operated on in the Cancer Institute and Imam Khomieni Hospital with a diagnosis of colorectal cancer were used to describe distribution of the colorectal carcinoma by age, gender, tumor subsite and pathology, and stage at diagnosis.
  • RESULTS: There were 403 (96.2 percent) cases of adenocarcinoma.
  • Patients were divided into two age groups (40 years and younger, and older than 40 years); 16.4 percent of patients had tumors in the proximal colon and 83.6 percent in distal parts.
  • Most patients were Stage II and III (48.1 and 33.4 percent, respectively).
  • Most patients in the younger age group were Stage III (45 percent) and in the older age group were Stage II (53.2 percent; P<0.001).
  • There were no differences in stage and tumor differentiation between two genders, but most of the patients with tumors in proximal colon were males (62.5 percent; P=0.1).
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Colorectal Neoplasms / epidemiology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525859.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Sadahiro S, Mitomi T, Noto T, Kumada K, Hiki Y, Yamakawa T, Amano T, Oki S, Otani Y, Oka H, Takahashi T, Takemiya S, Nishiyama K, Yamamura T, Tsuchiya S, Ogawa N, Study Group on Postoperative Adjuvant Chemotherapy in Kanagawa Prefecture: [Multicenter comparative study of the recurrence-inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection]. Gan To Kagaku Ryoho; 2005 Jul;32(7):997-1005
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 501 patients consisting of 252 patients with stage III/IV colon cancer (Colorectal Cancer Handling Rules, 4th Ed.) for which macroscopic curative resection was possible and 249 patients with stage II/III/IV rectal cancer (ibid, 4th Ed.) were registered from 40 participating institutions.
  • The patients were randomly allocated to two groups with colon cancer and rectal cancer employed as stratification factors.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Fluorouracil / analogs & derivatives. Rectal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044962.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 50SG953SK6 / Mitomycin; 56HH86ZVCT / Uracil; HA82M3RAB2 / 1-hexylcarbamoyl-5-fluorouracil; U3P01618RT / Fluorouracil
  •  go-up   go-down


94. Qureshi AU, Iqbal M, Gondal KM: Transhiatal esophageal surgery for malignancy--a 7-year experience at a tertiary care hospital. J Coll Physicians Surg Pak; 2009 Jul;19(7):413-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All underwent transhiatal esophagectomy and gastric tube or colon was used as the conduit to restore continuity.
  • The TNM staging were stage I, IIa, IIb, III and IV in zero (0), 5 (11%), 10 (22%), 24 (57.8%) and 3 (7.1%) respectively.
  • The frequency of complications is lower as compared to transthoracic approach and the early stage of presentation can lead to high 5-year survival ratios.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19576147.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


95. Park IJ, Choi GS, Lim KH, Kang BM, Jun SH: Different patterns of lymphatic spread of sigmoid, rectosigmoid, and rectal cancers. Ann Surg Oncol; 2008 Dec;15(12):3478-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For stage III disease, the local recurrence rate was significantly higher in the RA group; the disease-free survival rate was higher in the SC group, and the RS group showed results similar to those of the RA group.
  • Oncologic results were slightly unfavorable to sigmoid colon, and showed data similar to those of rectal cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma, Mucinous / secondary. Carcinoma, Signet Ring Cell / secondary. Lymph Nodes / pathology. Rectal Neoplasms / pathology. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2010 Jan;17(1):346-7 [19841983.001]
  • (PMID = 18830668.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Fernandes LC, Kim SB, Matos D: Cytokeratins and carcinoembryonic antigen in diagnosis, staging and prognosis of colorectal adenocarcinoma. World J Gastroenterol; 2005 Feb 7;11(5):645-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratins and carcinoembryonic antigen in diagnosis, staging and prognosis of colorectal adenocarcinoma.
  • AIM: To evaluate the serum levels of cytokeratins and carcinoembryonic antigen (CEA) in diagnosis, staging and prognosis of patients with colorectal adenocarcinoma.
  • RESULTS: In the diagnosis of patients with colorectal adenocarcinoma, CEA showed a sensitivity of 56%, a specificity of 95%, a positive predictive value of 94%, a negative predictive value of 50% and an accuracy of 76.8%.
  • There was a statistically significant difference between the patients with stage IV lesions and those with stages I, II and III tumors.
  • With regard to CEA, the average level was 14.2 ng/mL in patients with stage I lesions, 8.5 ng/mL in patients with stage II lesions, 8.0 ng/mL in patients with stage III lesions and 87.7 ng/mL in patients with stage IV lesions.
  • In relation to TPA-M, the levels were 153.1 U/L in patients with stage I tumors, 106.5 U/L in patients with stage II tumors, 136.3 U/L in patients with stage III tumors and 464.3 U/L in patients with stage IV tumors.
  • CONCLUSION: Cytokeratins demonstrate a greater sensitivity than CEA in the diagnosis of colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoembryonic Antigen / blood. Colorectal Neoplasms / pathology. Keratins / blood. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655814.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC4250731
  •  go-up   go-down


97. Givalos N, Gakiopoulou H, Skliri M, Bousboukea K, Konstantinidou AE, Korkolopoulou P, Lelouda M, Kouraklis G, Patsouris E, Karatzas G: Replication protein A is an independent prognostic indicator with potential therapeutic implications in colon cancer. Mod Pathol; 2007 Feb;20(2):159-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Replication protein A is an independent prognostic indicator with potential therapeutic implications in colon cancer.
  • Experimental studies in colon cancer cell lines have shown that RPA protein may be the target of cytotoxins designed to inhibit cellular proliferation.
  • This is the first study to investigate the expression of RPA1 and RPA2 subunits of RPA protein and assess their prognostic value in colon cancer patients.
  • We analyzed immunohistochemically the expression of RPA1 and RPA2 proteins in a series of 130 colon cancer resection specimens in relation to conventional clinicopathological parameters and patients' survival.
  • Statistical significant positive associations emerged between: (a) RPA1 and RPA2 protein expressions (P=0.0001), (b) RPA1 and RPA2 labelling indices (LIs) and advanced stage of the disease (P=0.001 and 0.003, respectively), (c) RPA1 and RPA2 LIs and the presence of lymph node metastasis (P=0.002 and 0.004, respectively), (d) RPA1 LI and the number of infiltrated lymph nodes (P=0.021), (e) RPA2 LI and histological grade of carcinomas (P=0.05).
  • Statistical significant differences according to the expression of RPA1 and RPA2 proteins were also noticed in the survival of stage II (P<0.00001 and 0.0016, respectively) and stage III (P=0.0029 and 0.0079, respectively) patients.
  • In conclusion, RPA1 and RPA2 proteins appear to be useful prognostic indicators in colon cancer patients and attractive therapeutic targets for regulation by tumor suppressors or other proteins involved in the control of cell proliferation.
  • [MeSH-major] Adenocarcinoma / metabolism. Colon / metabolism. Colonic Neoplasms / metabolism. Replication Protein A / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17361204.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RPA1 protein, human; 0 / Replication Protein A; EC 2.7.7.7 / RPA2 protein, human
  •  go-up   go-down


98. Vaccaro CA, Im V, Rossi GL, Quintana GO, Benati ML, Perez de Arenaza D, Bonadeo FA: Lymph node ratio as prognosis factor for colon cancer treated by colorectal surgeons. Dis Colon Rectum; 2009 Jul;52(7):1244-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node ratio as prognosis factor for colon cancer treated by colorectal surgeons.
  • PURPOSE: This study was designed to assess the prognostic value of the lymph node ratio in patients with colon cancer treated by colorectal specialists.
  • METHODS: Three hundred and sixty-two Stage III consecutive cases were analyzed based on quartiles: lymph node ratio 1 (>0 and <0.06); lymph node ratio 2 (between 0.06 and 0.12); lymph node ratio 3 (>0.12 and <0.25); lymph node ratio 4 (>or=0.25).
  • CONCLUSION: A lymph node ratio >or=0.25 was an independent prognostic factor in Stage III colon adenocarcinoma regardless of the number positive nodes.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Lymph Node Excision. Lymph Nodes / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19571700.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Janson M, Edlund G, Kressner U, Lindholm E, Påhlman L, Skullman S, Anderberg B, Haglind E: Analysis of patient selection and external validity in the Swedish contribution to the COLOR trial. Surg Endosc; 2009 Aug;23(8):1764-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The colon cancer laparoscopic or open resection (COLOR) trial is an international, randomised controlled trial comparing outcomes of open and laparoscopic surgery for colon cancer.
  • DESIGN: At eight centres, which included 391 of the 422 Swedish patients, a local database search was performed to identify retrospectively all patients (n = 2,384) who underwent surgery for colon cancer during the inclusion period, and data was retrieved from medical records.
  • Relative to group 1, patients in group 4 had a significantly higher American Society of Anaesthesiologists (ASA) score, more advanced tumour stage and difference regarding the resections performed.
  • Results showed that 1470 patients (62%) could be calculated as feasible for laparoscopic colon resection (LCR) in a clinical, nontrial situation.
  • In Sweden, 50-60% of colon cancer patients can be operated on by laparoscopy.
  • [MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Laparoscopy. Patient Selection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2005 Jul;6(7):477-84 [15992696.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] J Health Serv Res Policy. 1999 Apr;4(2):112-21 [10387403.001]
  • [Cites] JAMA. 2001 Apr 18;285(15):1987-91 [11308435.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1718-26 [15894098.001]
  • [Cites] Surg Endosc. 2005 May;19(5):687-92 [15798899.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] Anesthesiology. 1978 Oct;49(4):233-6 [697075.001]
  • [Cites] Int J Technol Assess Health Care. 2003 Winter;19(1):8-16 [12701935.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Br J Surg. 2005 Jan;92(1):94-100 [15521083.001]
  • [Cites] Surg Endosc. 2007 May;21(5):747-53 [17342556.001]
  • [Cites] Br J Surg. 2004 Apr;91(4):409-17 [15048739.001]
  • [Cites] Arch Surg. 2007 Mar;142(3):298-303 [17372057.001]
  • [Cites] Surg Endosc. 2002 Jun;16(6):949-53 [12163961.001]
  • [Cites] Health Technol Assess. 2005 Sep;9(35):1-186, iii-iv [16153352.001]
  • (PMID = 19057955.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


100. Kuebler JP, Colangelo L, O'Connell MJ, Smith RE, Yothers G, Begovic M, Robinson B, Seay TE, Wolmark N: Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis. Cancer; 2007 Nov 1;110(9):1945-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis.
  • BACKGROUND: Cases of severe gastrointestinal toxicity were monitored prospectively during NSABP C-07, a randomized clinical trial of adjuvant therapy for patients with stage II/III colon cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colonic Diseases / chemically induced. Colonic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17853393.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00004931
  • [Grant] United States / NCI NIH HHS / CA / U10-CA-12027; United States / NCI NIH HHS / CA / U10-CA-37377; United States / NCI NIH HHS / CA / U10-CA-69651; United States / NCI NIH HHS / CA / U10-CA-69974
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement